JPWO2007126067A1 - Non-aqueous adhesive composition, patch and method for producing the patch - Google Patents
Non-aqueous adhesive composition, patch and method for producing the patch Download PDFInfo
- Publication number
- JPWO2007126067A1 JPWO2007126067A1 JP2008513298A JP2008513298A JPWO2007126067A1 JP WO2007126067 A1 JPWO2007126067 A1 JP WO2007126067A1 JP 2008513298 A JP2008513298 A JP 2008513298A JP 2008513298 A JP2008513298 A JP 2008513298A JP WO2007126067 A1 JPWO2007126067 A1 JP WO2007126067A1
- Authority
- JP
- Japan
- Prior art keywords
- sensitive adhesive
- patch
- polyvalent metal
- adhesive composition
- aqueous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 26
- 239000000853 adhesive Substances 0.000 title description 25
- 230000001070 adhesive effect Effects 0.000 title description 25
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims abstract description 94
- 239000010410 layer Substances 0.000 claims abstract description 55
- 150000002736 metal compounds Chemical class 0.000 claims abstract description 41
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- 229920003176 water-insoluble polymer Polymers 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000011259 mixed solution Substances 0.000 claims abstract description 24
- 239000002738 chelating agent Substances 0.000 claims abstract description 17
- 238000004132 cross linking Methods 0.000 claims abstract description 17
- 239000006185 dispersion Substances 0.000 claims abstract description 17
- 239000002904 solvent Substances 0.000 claims abstract description 16
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 12
- 239000013522 chelant Substances 0.000 claims abstract description 10
- 125000000524 functional group Chemical group 0.000 claims abstract description 10
- 239000000178 monomer Substances 0.000 claims description 50
- 229940079593 drug Drugs 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims description 21
- 239000004014 plasticizer Substances 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 238000010030 laminating Methods 0.000 claims description 3
- 238000004581 coalescence Methods 0.000 claims 1
- 238000000576 coating method Methods 0.000 description 56
- 239000011248 coating agent Substances 0.000 description 53
- -1 fatty acid ester Chemical class 0.000 description 45
- 210000003491 skin Anatomy 0.000 description 37
- 239000000243 solution Substances 0.000 description 22
- 230000036407 pain Effects 0.000 description 21
- 238000001035 drying Methods 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 14
- 229920000058 polyacrylate Polymers 0.000 description 14
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 239000003431 cross linking reagent Substances 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 8
- 229920001577 copolymer Polymers 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 150000002430 hydrocarbons Chemical group 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000003002 pH adjusting agent Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 229940114077 acrylic acid Drugs 0.000 description 7
- 239000012790 adhesive layer Substances 0.000 description 7
- 239000012948 isocyanate Substances 0.000 description 7
- 239000003505 polymerization initiator Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000003522 acrylic cement Substances 0.000 description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 150000002513 isocyanates Chemical class 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- 239000011505 plaster Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 5
- 238000013329 compounding Methods 0.000 description 5
- 229920001971 elastomer Polymers 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 229920006264 polyurethane film Polymers 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229940048053 acrylate Drugs 0.000 description 4
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000806 elastomer Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000007720 emulsion polymerization reaction Methods 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000004745 nonwoven fabric Substances 0.000 description 4
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 229940043430 calcium compound Drugs 0.000 description 3
- 150000001674 calcium compounds Chemical class 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 3
- 229940043276 diisopropanolamine Drugs 0.000 description 3
- 229940031569 diisopropyl sebacate Drugs 0.000 description 3
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 150000002681 magnesium compounds Chemical class 0.000 description 3
- 229940065472 octyl acrylate Drugs 0.000 description 3
- 229960003330 pentetic acid Drugs 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- VXYADVIJALMOEQ-UHFFFAOYSA-K tris(lactato)aluminium Chemical compound CC(O)C(=O)O[Al](OC(=O)C(C)O)OC(=O)C(C)O VXYADVIJALMOEQ-UHFFFAOYSA-K 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- KANZWHBYRHQMKZ-UHFFFAOYSA-N 2-ethenylpyrazine Chemical compound C=CC1=CN=CC=N1 KANZWHBYRHQMKZ-UHFFFAOYSA-N 0.000 description 2
- WDQMWEYDKDCEHT-UHFFFAOYSA-N 2-ethylhexyl 2-methylprop-2-enoate Chemical compound CCCCC(CC)COC(=O)C(C)=C WDQMWEYDKDCEHT-UHFFFAOYSA-N 0.000 description 2
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 2
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 2
- YWXYYJSYQOXTPL-JGWLITMVSA-N [(3r,3ar,6s,6as)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-JGWLITMVSA-N 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- HDYRYUINDGQKMC-UHFFFAOYSA-M acetyloxyaluminum;dihydrate Chemical compound O.O.CC(=O)O[Al] HDYRYUINDGQKMC-UHFFFAOYSA-M 0.000 description 2
- 229920006243 acrylic copolymer Polymers 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 2
- 229940009827 aluminum acetate Drugs 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 2
- 239000001639 calcium acetate Substances 0.000 description 2
- 235000011092 calcium acetate Nutrition 0.000 description 2
- 229960005147 calcium acetate Drugs 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229960002896 clonidine Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000003851 corona treatment Methods 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 229940031578 diisopropyl adipate Drugs 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 229960000192 felbinac Drugs 0.000 description 2
- 229960002390 flurbiprofen Drugs 0.000 description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Natural products O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 229960003883 furosemide Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 229940125697 hormonal agent Drugs 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 229940075495 isopropyl palmitate Drugs 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
- 239000011654 magnesium acetate Substances 0.000 description 2
- 229940069446 magnesium acetate Drugs 0.000 description 2
- 235000011285 magnesium acetate Nutrition 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 239000000347 magnesium hydroxide Substances 0.000 description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
- 235000012254 magnesium hydroxide Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 description 2
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 2
- ANISOHQJBAQUQP-UHFFFAOYSA-N octyl prop-2-enoate Chemical compound CCCCCCCCOC(=O)C=C ANISOHQJBAQUQP-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 2
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000009832 plasma treatment Methods 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 2
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 229940124535 smoking cessation aid Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 238000004381 surface treatment Methods 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 2
- 235000019801 trisodium phosphate Nutrition 0.000 description 2
- 229960000859 tulobuterol Drugs 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- SSJXIUAHEKJCMH-OLQVQODUSA-N (1s,2r)-cyclohexane-1,2-diamine Chemical compound N[C@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-OLQVQODUSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OSSNTDFYBPYIEC-UHFFFAOYSA-N 1-ethenylimidazole Chemical compound C=CN1C=CN=C1 OSSNTDFYBPYIEC-UHFFFAOYSA-N 0.000 description 1
- DCRYNQTXGUTACA-UHFFFAOYSA-N 1-ethenylpiperazine Chemical compound C=CN1CCNCC1 DCRYNQTXGUTACA-UHFFFAOYSA-N 0.000 description 1
- PBGPBHYPCGDFEZ-UHFFFAOYSA-N 1-ethenylpiperidin-2-one Chemical compound C=CN1CCCCC1=O PBGPBHYPCGDFEZ-UHFFFAOYSA-N 0.000 description 1
- GLXBPZNFNSLJBS-UHFFFAOYSA-N 11-methyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCCCCCCC(C)C GLXBPZNFNSLJBS-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 1
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 description 1
- ZZIZZTHXZRDOFM-UHFFFAOYSA-N 2-(2-ethoxyphenoxy)ethyl-[1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl]azanium;chloride Chemical compound Cl.CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- DPBJAVGHACCNRL-UHFFFAOYSA-N 2-(dimethylamino)ethyl prop-2-enoate Chemical compound CN(C)CCOC(=O)C=C DPBJAVGHACCNRL-UHFFFAOYSA-N 0.000 description 1
- XNCSCQSQSGDGES-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(O)=O XNCSCQSQSGDGES-UHFFFAOYSA-N 0.000 description 1
- DMQQXDPCRUGSQB-UHFFFAOYSA-N 2-[3-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CCCN(CC(O)=O)CC(O)=O DMQQXDPCRUGSQB-UHFFFAOYSA-N 0.000 description 1
- TXBCBTDQIULDIA-UHFFFAOYSA-N 2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)CO TXBCBTDQIULDIA-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- PGMMQIGGQSIEGH-UHFFFAOYSA-N 2-ethenyl-1,3-oxazole Chemical compound C=CC1=NC=CO1 PGMMQIGGQSIEGH-UHFFFAOYSA-N 0.000 description 1
- JDCUKFVNOWJNBU-UHFFFAOYSA-N 2-ethenyl-1,3-thiazole Chemical compound C=CC1=NC=CS1 JDCUKFVNOWJNBU-UHFFFAOYSA-N 0.000 description 1
- MZNSQRLUUXWLSB-UHFFFAOYSA-N 2-ethenyl-1h-pyrrole Chemical compound C=CC1=CC=CN1 MZNSQRLUUXWLSB-UHFFFAOYSA-N 0.000 description 1
- ZDHWTWWXCXEGIC-UHFFFAOYSA-N 2-ethenylpyrimidine Chemical compound C=CC1=NC=CC=N1 ZDHWTWWXCXEGIC-UHFFFAOYSA-N 0.000 description 1
- SFPNZPQIIAJXGL-UHFFFAOYSA-N 2-ethoxyethyl 2-methylprop-2-enoate Chemical compound CCOCCOC(=O)C(C)=C SFPNZPQIIAJXGL-UHFFFAOYSA-N 0.000 description 1
- MUHFRORXWCGZGE-KTKRTIGZSA-N 2-hydroxyethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCO MUHFRORXWCGZGE-KTKRTIGZSA-N 0.000 description 1
- HFCUBKYHMMPGBY-UHFFFAOYSA-N 2-methoxyethyl prop-2-enoate Chemical compound COCCOC(=O)C=C HFCUBKYHMMPGBY-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- PCGWQMQRGXCNAX-UHFFFAOYSA-N 3-(3-sulfopropylsulfonyl)propane-1-sulfonic acid Chemical group S(=O)(=O)(O)CCCS(=O)(=O)CCCS(=O)(=O)O PCGWQMQRGXCNAX-UHFFFAOYSA-N 0.000 description 1
- KWYJDIUEHHCHCZ-UHFFFAOYSA-N 3-[2-[bis(2-carboxyethyl)amino]ethyl-(2-carboxyethyl)amino]propanoic acid Chemical compound OC(=O)CCN(CCC(O)=O)CCN(CCC(O)=O)CCC(O)=O KWYJDIUEHHCHCZ-UHFFFAOYSA-N 0.000 description 1
- MXRGSJAOLKBZLU-UHFFFAOYSA-N 3-ethenylazepan-2-one Chemical compound C=CC1CCCCNC1=O MXRGSJAOLKBZLU-UHFFFAOYSA-N 0.000 description 1
- CFZDMXAOSDDDRT-UHFFFAOYSA-N 4-ethenylmorpholine Chemical compound C=CN1CCOCC1 CFZDMXAOSDDDRT-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- HSEYYGFJBLWFGD-UHFFFAOYSA-N 4-methylsulfanyl-2-[(2-methylsulfanylpyridine-3-carbonyl)amino]butanoic acid Chemical compound CSCCC(C(O)=O)NC(=O)C1=CC=CN=C1SC HSEYYGFJBLWFGD-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- WDPFQABQVGJEBZ-MAKOZQESSA-N Bothermon Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 WDPFQABQVGJEBZ-MAKOZQESSA-N 0.000 description 1
- AFWTZXXDGQBIKW-UHFFFAOYSA-N C14 surfactin Natural products CCCCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 AFWTZXXDGQBIKW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- YIVJZNGAASQVEM-UHFFFAOYSA-N Lauroyl peroxide Chemical compound CCCCCCCCCCCC(=O)OOC(=O)CCCCCCCCCCC YIVJZNGAASQVEM-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- WJEIYVAPNMUNIU-UHFFFAOYSA-N [Na].OC(O)=O Chemical compound [Na].OC(O)=O WJEIYVAPNMUNIU-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- XYLMUPLGERFSHI-UHFFFAOYSA-N alpha-Methylstyrene Chemical compound CC(=C)C1=CC=CC=C1 XYLMUPLGERFSHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940103272 aluminum potassium sulfate Drugs 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- LCQXXBOSCBRNNT-UHFFFAOYSA-K ammonium aluminium sulfate Chemical compound [NH4+].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O LCQXXBOSCBRNNT-UHFFFAOYSA-K 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229960001889 buprenorphine hydrochloride Drugs 0.000 description 1
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000012986 chain transfer agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 229920006026 co-polymeric resin Polymers 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 150000001869 cobalt compounds Chemical class 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PGZIKUPSQINGKT-UHFFFAOYSA-N dialuminum;dioxido(oxo)silane Chemical compound [Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O PGZIKUPSQINGKT-UHFFFAOYSA-N 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 description 1
- 238000003618 dip coating Methods 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- SMVRDGHCVNAOIN-UHFFFAOYSA-L disodium;1-dodecoxydodecane;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC SMVRDGHCVNAOIN-UHFFFAOYSA-L 0.000 description 1
- CGDDQFMPGMYYQP-UHFFFAOYSA-N disopyramide phosphate Chemical compound OP(O)(O)=O.C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 CGDDQFMPGMYYQP-UHFFFAOYSA-N 0.000 description 1
- 229960001863 disopyramide phosphate Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- GMSCBRSQMRDRCD-UHFFFAOYSA-N dodecyl 2-methylprop-2-enoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)=C GMSCBRSQMRDRCD-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UIWXSTHGICQLQT-UHFFFAOYSA-N ethenyl propanoate Chemical compound CCC(=O)OC=C UIWXSTHGICQLQT-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- IFQUWYZCAGRUJN-UHFFFAOYSA-N ethylenediaminediacetic acid Chemical compound OC(=O)CNCCNCC(O)=O IFQUWYZCAGRUJN-UHFFFAOYSA-N 0.000 description 1
- 238000007765 extrusion coating Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AVIYEYCFMVPYST-UHFFFAOYSA-N hexane-1,3-diol Chemical compound CCCC(O)CCO AVIYEYCFMVPYST-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 229960003390 magnesium sulfate Drugs 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000002697 manganese compounds Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KFIGICHILYTCJF-UHFFFAOYSA-N n'-methylethane-1,2-diamine Chemical compound CNCCN KFIGICHILYTCJF-UHFFFAOYSA-N 0.000 description 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
- 150000002816 nickel compounds Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229940059574 pentaerithrityl Drugs 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920005646 polycarboxylate Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920005749 polyurethane resin Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- UIIIBRHUICCMAI-UHFFFAOYSA-N prop-2-ene-1-sulfonic acid Chemical compound OS(=O)(=O)CC=C UIIIBRHUICCMAI-UHFFFAOYSA-N 0.000 description 1
- PZZICILSCNDOKK-UHFFFAOYSA-N propane-1,2,3-triamine Chemical compound NCC(N)CN PZZICILSCNDOKK-UHFFFAOYSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- KFUSANSHCADHNJ-UHFFFAOYSA-N pyridine-3-carbohydrazide Chemical compound NNC(=O)C1=CC=CN=C1 KFUSANSHCADHNJ-UHFFFAOYSA-N 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- 239000007870 radical polymerization initiator Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 229940077082 red pepper extract Drugs 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229920006268 silicone film Polymers 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- NJGWOFRZMQRKHT-UHFFFAOYSA-N surfactin Natural products CC(C)CCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-UHFFFAOYSA-N 0.000 description 1
- NJGWOFRZMQRKHT-WGVNQGGSSA-N surfactin C Chemical compound CC(C)CCCCCCCCC[C@@H]1CC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-WGVNQGGSSA-N 0.000 description 1
- 229960003198 tamsulosin hydrochloride Drugs 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 150000003606 tin compounds Chemical class 0.000 description 1
- 150000003609 titanium compounds Chemical class 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 238000001771 vacuum deposition Methods 0.000 description 1
- 229920006163 vinyl copolymer Polymers 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 150000003752 zinc compounds Chemical class 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J11/00—Features of adhesives not provided for in group C09J9/00, e.g. additives
- C09J11/02—Non-macromolecular additives
- C09J11/04—Non-macromolecular additives inorganic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J9/00—Adhesives characterised by their physical nature or the effects produced, e.g. glue sticks
- C09J9/02—Electrically-conducting adhesives
Abstract
本発明は、多価金属イオンと架橋点を形成する官能基を有する非水溶性高分子化合物(A)と、多価金属化合物(B)を含有することを特徴とする非水系粘着剤組成物および該非水系粘着剤組成物が支持体に積層されてなる貼付剤に関する。また、本発明は、多価金属化合物(B)と、該多価金属化合物(B)とキレートを形成するキレート剤(C)を含水溶媒に予め溶解し、pHを7以上に調整した混合溶液を調製した後、該混合溶液と、多価金属イオンと架橋点を形成する官能基を有する非水溶性高分子化合物(A)とを混合して水分散液を調製し、該水分散液を、ライナーまたは支持体に塗工し、乾燥して非水系粘着剤層を設けることを特徴とする貼付剤の製造方法に関する。The present invention relates to a nonaqueous pressure-sensitive adhesive composition comprising a water-insoluble polymer compound (A) having a functional group that forms a crosslinking point with a polyvalent metal ion, and a polyvalent metal compound (B). And a patch comprising the non-aqueous pressure-sensitive adhesive composition laminated on a support. The present invention also provides a mixed solution in which a polyvalent metal compound (B) and a chelating agent (C) that forms a chelate with the polyvalent metal compound (B) are previously dissolved in a water-containing solvent and the pH is adjusted to 7 or more. Then, the mixed solution is mixed with a water-insoluble polymer compound (A) having a functional group that forms a crosslinking point with a polyvalent metal ion to prepare an aqueous dispersion. The present invention also relates to a method for producing a patch, which is coated on a liner or a support and dried to provide a non-aqueous pressure-sensitive adhesive layer.
Description
本発明は、非水系粘着剤組成物、該非水系粘着剤組成物を用いた貼付剤、および貼付剤の製造方法に関する。
本願は、2006年4月28日に出願された特願2006−126716号に基づいて優先権を主張し、その内容をここに援用する。The present invention relates to a non-aqueous adhesive composition, a patch using the non-aqueous adhesive composition, and a method for producing the patch.
This application claims priority based on Japanese Patent Application No. 2006-126716 for which it applied on April 28, 2006, and uses the content here.
従来、薬剤を経皮吸収させるための製剤として、たとえば、膏体(粘着剤組成物)が支持体に積層されてなる貼付剤等が用いられている。
貼付剤には、ポリアクリル酸などのポリマーを水で膨潤させたものを使用した、いわゆる含水系貼付剤や、スチレン−イソプレンースチレンブロック共重合体(SIS)やポリイソブテン等のゴム系粘着剤またはアクリル系粘着剤を使用した、いわゆる非水系貼付剤等がある。Conventionally, as a preparation for percutaneously absorbing a drug, for example, a patch in which a plaster (adhesive composition) is laminated on a support has been used.
As the patch, a so-called hydrous patch using a polymer such as polyacrylic acid swollen with water, a rubber-based adhesive such as styrene-isoprene-styrene block copolymer (SIS) or polyisobutene, or There are so-called non-aqueous patches using an acrylic adhesive.
含水系貼付剤においては、皮膚に貼付中に、水が蒸散して膏体が硬くなったり、膏体の粘着性が損なわれたりするという問題がある。
一方、非水系貼付剤においては、含水系貼付剤で問題となるような経時変化は生じず、また、膏体の層(粘着剤層)が薄くても高い粘着力が得られる点で、含水系貼付剤より効果的である。
しかしながら、非水系貼付剤は、皮膚から剥がした際、膏体の粘着力が強すぎて皮膚の角質層が剥離する等の問題がある。In the case of a water-containing patch, there is a problem that water is evaporated and the paste becomes hard during sticking to the skin, or the adhesiveness of the paste is impaired.
On the other hand, non-aqueous patches do not change over time, which is a problem with hydrous patches, and high adhesive strength can be obtained even if the plaster layer (adhesive layer) is thin. It is more effective than the system patch.
However, the non-aqueous patch has a problem that, when peeled from the skin, the adhesive strength of the plaster is too strong and the stratum corneum of the skin peels off.
非水系貼付剤における上記問題を解決するため、たとえば、アクリル系共重合体と、分子量800以上であり、疎水性パラメーターが−20以上45以下である室温で液状もしくはペースト状の可塑剤と、架橋剤(イソシアネート系架橋剤)からなる、人皮膚に対して良好な粘着性を有する皮膚用粘着剤組成物(特許文献1参照)等が提案されている。
また、粘着剤層中に、(メタ)アクリル酸アルキルエステルおよび官能性単量体を必須成分とする単量体混合物を共重合してなるアクリル系共重合体と、炭素数が12〜16の高級脂肪酸と炭素数が1〜4の低級1価アルコールからなる脂肪酸エステルと、炭素数が8〜10の高級脂肪酸とグリセリンからなるモノグリセリドと、経皮吸収用薬物が含有されていると共に、粘着剤層がイソシアネート系架橋剤等により架橋されている、皮膚刺激性の低い経皮吸収製剤(特許文献2参照)等が提案されている。
また、粘着剤中に塩酸ブプレノルフィン及び/又はブプレノルフィンと吸収促進剤とを含有する膏体層を支持体の片面に設けた経皮吸収製剤であって、該吸収促進剤が炭素数6〜8の脂肪酸のモノグリセリドとミリスチン酸イソプロピルとの組合せよりなり、膏体層が架橋剤により架橋されている、薬物の皮膚透過性に優れた経皮吸収製剤(特許文献3参照)等が提案されている。
In addition, an acrylic copolymer obtained by copolymerizing a monomer mixture containing (meth) acrylic acid alkyl ester and a functional monomer as essential components in the pressure-sensitive adhesive layer, and a carbon number of 12 to 16 A fatty acid ester comprising a higher fatty acid and a lower monohydric alcohol having 1 to 4 carbon atoms, a monoglyceride comprising a higher fatty acid having 8 to 10 carbon atoms and glycerin, and a transdermally absorbable drug, and an adhesive A percutaneous absorption preparation (see Patent Document 2) having a low skin irritation, in which a layer is crosslinked with an isocyanate-based crosslinking agent or the like, has been proposed.
Moreover, it is a percutaneous absorption preparation which provided the plaster layer containing buprenorphine hydrochloride and / or buprenorphine and an absorption enhancer in one side of the support, and the absorption enhancer has 6 to 8 carbon atoms. A transdermal absorption preparation (see Patent Document 3) excellent in skin permeability of a drug, comprising a combination of a fatty acid monoglyceride and isopropyl myristate and having a plaster layer crosslinked with a crosslinking agent has been proposed.
しかしながら、特許文献1〜2に記載の技術では、貼付剤の製造過程において、乾燥や加熱熟成に数十分〜2.5日間を要するため、エネルギーコストが高くなる等の製造上の問題がある。
たとえば、特許文献1に記載の実施例(イソシアネート系架橋剤を用いた場合)では、剥離シート(剥離フィルム)上に粘着剤層を形成する際の乾燥条件が80℃で20分間である(実施例1、段落[0040]参照)。
また、特許文献2に記載の実施例(イソシアネート系架橋剤を用いた場合)では、支持体(積層フィルム)に粘着剤層を貼り合わせた後の加熱熟成条件が70℃で60時間である(実施例および比較例、段落[0038]参照)。However, the techniques described in Patent Documents 1 and 2 have production problems such as high energy costs because it takes several tens of minutes to 2.5 days for drying and heat aging in the manufacturing process of the patch. .
For example, in the example described in Patent Document 1 (when an isocyanate-based crosslinking agent is used), the drying condition for forming the pressure-sensitive adhesive layer on the release sheet (release film) is 80 ° C. for 20 minutes (implementation). See Example 1, paragraph [0040]).
Moreover, in the Example (when an isocyanate type crosslinking agent is described) described in Patent Document 2, the heat aging condition after bonding the pressure-sensitive adhesive layer to the support (laminated film) is 70 ° C. for 60 hours ( Examples and Comparative Examples, see paragraph [0038]).
また、イソシアネート系架橋剤以外の架橋剤、たとえば特許文献3に記載の実施例(実施例10、段落[0048]参照)などのような有機金属塩や、金属アルコラートを用いた場合についても、貼付剤の製造過程で数日間を要したり、または粘着剤層用塗工液を支持体面に塗工中に粘度が上昇して均一に塗工できず、塗工時間が制限されたり等、製造性に劣る問題がある。
さらに、得られる貼付剤は、必ずしも皮膚に対しての粘着性と、剥離時の痛みの抑制とが同時に満足されるものではない。In addition, a cross-linking agent other than an isocyanate-based cross-linking agent, for example, an organic metal salt such as an example described in Patent Document 3 (see Example 10, paragraph [0048]) or a metal alcoholate is also used. It takes several days in the manufacturing process of the adhesive, or the viscosity increases during the application of the adhesive layer coating liquid to the support surface, and it cannot be applied uniformly, and the coating time is limited. There is an inferior problem.
Furthermore, the obtained patch does not necessarily satisfy the adhesiveness to the skin and the suppression of pain at the time of peeling at the same time.
本発明は、上記事情に鑑みてなされたものであり、製造性に優れ、皮膚に対して良好な粘着性を有し、かつ剥離時の痛みが抑制された貼付剤を提供する非水系粘着剤組成物、貼付剤および貼付剤の製造方法を提供することを課題とする。 The present invention has been made in view of the above circumstances, and is a non-aqueous pressure-sensitive adhesive that provides a patch having excellent manufacturability, good adhesiveness to the skin, and reduced pain during peeling. It is an object to provide a composition, a patch, and a method for producing the patch.
本発明者らは、鋭意検討した結果、上記課題を解決するために本発明を完成するに至った。
すなわち、本発明の第一の実施態様は、多価金属イオンと架橋点を形成する官能基を有する非水溶性高分子化合物(A)と、多価金属化合物(B)を含有することを特徴とする非水系粘着剤組成物である。
また、本発明においては、前記多価金属化合物(B)は水溶性多価金属化合物であることが好ましい。
また、本発明においては、前記多価金属化合物(B)とキレートを形成するキレート剤(C)をさらに含有することが好ましい。
また、本発明においては、前記非水溶性高分子化合物(A)が、炭素数4〜12のアルキル基を含む(メタ)アクリル酸アルキルエステルから選ばれるモノマー単位と、カルボキシ基を含むモノマーから選ばれるモノマー単位とを有する重合体であることが好ましい。
また、本発明においては、可塑剤(D)をさらに含有することが好ましい。
また、本発明においては、薬物(E)をさらに含有することが好ましい。As a result of intensive studies, the present inventors have completed the present invention in order to solve the above problems.
That is, the first embodiment of the present invention comprises a water-insoluble polymer compound (A) having a functional group that forms a crosslinking point with a polyvalent metal ion, and a polyvalent metal compound (B). It is a non-aqueous pressure-sensitive adhesive composition.
In the present invention, the polyvalent metal compound (B) is preferably a water-soluble polyvalent metal compound.
Moreover, in this invention, it is preferable to contain further the chelating agent (C) which forms a chelate with the said polyvalent metal compound (B).
Moreover, in this invention, the said water-insoluble polymer compound (A) is chosen from the monomer unit chosen from the (meth) acrylic-acid alkylester containing a C4-C12 alkyl group, and the monomer containing a carboxy group. It is preferable that the polymer has a monomer unit.
Moreover, in this invention, it is preferable to contain a plasticizer (D) further.
In the present invention, it is preferable to further contain a drug (E).
また、本発明の第二の実施態様は、前記非水系粘着剤組成物が支持体に積層されてなる貼付剤である。
また、本発明の第三の実施態様は、多価金属化合物(B)と、該多価金属化合物(B)とキレートを形成するキレート剤(C)を含水溶媒に予め溶解し、pHを7以上に調整した混合溶液を調製した後、該混合溶液と、多価金属イオンと架橋点を形成する官能基を有する非水溶性高分子化合物(A)とを混合して水分散液を調製し、該水分散液を、ライナーまたは支持体に塗工し、乾燥して非水系粘着剤層を設けることを特徴とする貼付剤の製造方法である。Moreover, the 2nd embodiment of this invention is a patch by which the said non-aqueous adhesive composition is laminated | stacked on a support body.
In the third embodiment of the present invention, the polyvalent metal compound (B) and the chelating agent (C) that forms a chelate with the polyvalent metal compound (B) are previously dissolved in a water-containing solvent, and the pH is adjusted to 7 After preparing the mixed solution prepared as described above, the aqueous solution is prepared by mixing the mixed solution and the water-insoluble polymer compound (A) having a functional group that forms a crosslinking point with a polyvalent metal ion. The method for producing a patch is characterized in that the aqueous dispersion is applied to a liner or a support and dried to provide a non-aqueous pressure-sensitive adhesive layer.
本発明によれば、製造性に優れ、皮膚に対して良好な粘着性を有し、かつ剥離時の痛みが抑制された貼付剤を提供する非水系粘着剤組成物、貼付剤および貼付剤の製造方法を提供することができる。 According to the present invention, a non-aqueous pressure-sensitive adhesive composition, a patch, and a patch that provide a patch having excellent manufacturability, good adhesiveness to the skin, and reduced pain at the time of peeling. A manufacturing method can be provided.
≪非水系粘着剤組成物≫
本発明の非水系粘着剤組成物は、多価金属イオンと架橋点を形成する官能基を有する非水溶性高分子化合物(A)と、多価金属化合物(B)を含有するものである。
また、本発明の非水系粘着剤組成物は、好ましくは、前記多価金属化合物(B)とキレートを形成するキレート剤(C)をさらに含有する。
また、本発明の非水系粘着剤組成物は、好ましくは、可塑剤(D)をさらに含有する。
また、本発明の非水系粘着剤組成物は、好ましくは、薬物(E)をさらに含有する。≪Nonaqueous adhesive composition≫
The non-aqueous pressure-sensitive adhesive composition of the present invention contains a water-insoluble polymer compound (A) having a functional group that forms a crosslinking point with a polyvalent metal ion, and a polyvalent metal compound (B).
The non-aqueous pressure-sensitive adhesive composition of the present invention preferably further contains a chelating agent (C) that forms a chelate with the polyvalent metal compound (B).
The non-aqueous pressure-sensitive adhesive composition of the present invention preferably further contains a plasticizer (D).
Moreover, the non-aqueous pressure-sensitive adhesive composition of the present invention preferably further contains a drug (E).
本発明の非水系粘着剤組成物は、たとえば支持体層と非水系粘着剤層とライナー層からなる貼付剤(非水系貼付剤)の非水系粘着剤層を構成するものである。
係る非水系粘着剤組成物は、原料由来、製造工程または環境からの水分を含んでいてもよいが、該水分の含有量は少ないほど好ましい。具体的には、水分の含有量は、非水系粘着剤組成物中、5質量%以下であることが好ましく、より好ましくは2質量%以下である。水分の含有量を5質量%以下とすることにより、非水系粘着剤組成物の凝集力が高くなり、貼付剤の皮膚からの剥離性が向上する。たとえば、水分を0.5質量%程度含有する非水系粘着剤組成物は、本発明の効果が良好な非水系粘着剤組成物である。The non-aqueous pressure-sensitive adhesive composition of the present invention constitutes a non-aqueous pressure-sensitive adhesive layer of a patch (non-aqueous patch) comprising, for example, a support layer, a non-aqueous pressure-sensitive adhesive layer, and a liner layer.
The non-aqueous pressure-sensitive adhesive composition may contain moisture from the raw material, the manufacturing process, or the environment, but the smaller the moisture content, the better. Specifically, the water content is preferably 5% by mass or less, more preferably 2% by mass or less, in the non-aqueous pressure-sensitive adhesive composition. By setting the water content to 5% by mass or less, the cohesive force of the non-aqueous pressure-sensitive adhesive composition is increased, and the peelability of the patch from the skin is improved. For example, a non-aqueous pressure-sensitive adhesive composition containing about 0.5% by mass of water is a non-aqueous pressure-sensitive adhesive composition with good effects of the present invention.
<非水溶性高分子化合物(A)>
本発明において用いられる非水溶性高分子化合物(A)(以下、(A)成分ということがある。)は、多価金属イオンと架橋点を形成する官能基を有するものである。
本明細書および特許請求の範囲において「非水溶性高分子化合物」とは、20℃の水に対する溶解度が1mg/mL未満である高分子化合物を示す。
また、「多価金属イオンと架橋点を形成する官能基」とは、多価金属イオンをはさむように配位して環構造(キレート環)を形成する特性を有する基を意味し、本発明においてはカルボキシル基、アミノ基、スルホン基、ヒドロキシル基が好適なものとして挙げられ、なかでもカルボキシル基が特に好ましい。
係る(A)成分を含有することにより、貼付剤とした際に皮膚への粘着性が向上する。<Water-insoluble polymer compound (A)>
The water-insoluble polymer compound (A) (hereinafter sometimes referred to as component (A)) used in the present invention has a functional group that forms a crosslinking point with a polyvalent metal ion.
In the present specification and claims, the “water-insoluble polymer compound” refers to a polymer compound having a solubility in water at 20 ° C. of less than 1 mg / mL.
In addition, the “functional group that forms a cross-linking point with a polyvalent metal ion” means a group having a characteristic of forming a ring structure (chelate ring) by coordination with a polyvalent metal ion sandwiched between them. In the above, a carboxyl group, an amino group, a sulfone group, and a hydroxyl group are preferable, and among them, a carboxyl group is particularly preferable.
By containing the component (A), the adhesiveness to the skin is improved when a patch is prepared.
非水溶性高分子化合物(A)としては、なかでも、貼付剤とした際、皮膚に対しての粘着性が良好なことから、アクリル系高分子が好ましい。
アクリル系高分子のなかでも、(メタ)アクリル酸アルキルエステルから選ばれるモノマー単位、カルボキシ基を含むモノマーから選ばれるモノマー単位等を有する重合体が好ましく用いられる。
本明細書および特許請求の範囲において「モノマー単位」とは、重合体を構成する構成単位(単量体単位)を意味する。
「(メタ)アクリル酸」とは、メタクリル酸とアクリル酸の一方または両方を示す。
モノマー単位を提供する(メタ)アクリル酸アルキルエステルにおいて、アルキル基の炭素数は、粘着力が良好なことから、1〜30のものが好ましく、より好ましくは4〜20のものであり、特に好ましくは4〜12のものであり、直鎖状であっても分岐鎖状であってもよい。
該アルキル基としては、たとえば、ブチル、ペンチル、ヘキシル、ヘプチル、オクチル、ノニル、デシル、ウンデシル、ドデシル、トリデシル、テトラデシルなどの直鎖状アルキル基、2−エチルヘキシルなどの分岐鎖状アルキル基が挙げられる。
(メタ)アクリル酸アルキルエステルとして具体的には、アクリル酸エチル、アクリル酸n−ブチル、アクリル酸オクチル、アクリル酸2−エチルヘキシル、メタクリル酸2−エチルヘキシル、メタクリル酸メチル、メタクリル酸ドデシルが特に好ましい。
また、モノマー単位を提供するカルボキシ基を含むモノマーとして具体的には、(メタ)アクリル酸、イタコン酸、マレイン酸、無水マレイン酸等が挙げられる。なかでも、アクリル酸、メタクリル酸が特に好ましい。
アクリル系粘着剤において、上記モノマー単位を提供するモノマーは、1種単独で用いてもよく、2種以上を併用してもよい。
なかでも、該アクリル系高分子は、粘着性、架橋性、凝集性の点から、炭素数4〜12のアルキル基を含む(メタ)アクリル酸アルキルエステルから選ばれるモノマー単位と、カルボキシ基を含むモノマーから選ばれるモノマー単位とを有する重合体であることが好ましい。As the water-insoluble polymer compound (A), an acrylic polymer is preferable because of its good adhesiveness to the skin when used as a patch.
Among the acrylic polymers, a polymer having a monomer unit selected from (meth) acrylic acid alkyl ester, a monomer unit selected from a monomer containing a carboxy group, and the like is preferably used.
In the present specification and claims, “monomer unit” means a structural unit (monomer unit) constituting a polymer.
“(Meth) acrylic acid” refers to one or both of methacrylic acid and acrylic acid.
In the (meth) acrylic acid alkyl ester that provides a monomer unit, the alkyl group preferably has 1 to 30 carbon atoms, more preferably 4 to 20 carbon atoms, and particularly preferably has good adhesive strength. Are 4 to 12, and may be linear or branched.
Examples of the alkyl group include linear alkyl groups such as butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, and branched alkyl groups such as 2-ethylhexyl. .
Specifically, as the (meth) acrylic acid alkyl ester, ethyl acrylate, n-butyl acrylate, octyl acrylate, 2-ethylhexyl acrylate, 2-ethylhexyl methacrylate, methyl methacrylate, and dodecyl methacrylate are particularly preferable.
Specific examples of the monomer containing a carboxy group that provides a monomer unit include (meth) acrylic acid, itaconic acid, maleic acid, and maleic anhydride. Of these, acrylic acid and methacrylic acid are particularly preferable.
In the acrylic pressure-sensitive adhesive, the monomers providing the monomer units may be used alone or in combination of two or more.
Among these, the acrylic polymer contains a monomer unit selected from (meth) acrylic acid alkyl esters containing an alkyl group having 4 to 12 carbon atoms and a carboxy group from the viewpoints of adhesiveness, crosslinkability, and aggregation. A polymer having a monomer unit selected from monomers is preferred.
アクリル系高分子中の上記モノマー単位((メタ)アクリル酸アルキルエステルとカルボキシル基を含むモノマーの合計)の割合は、該アクリル系高分子を構成する全モノマー単位に対し、10〜100質量%が好ましく、40〜100質量%がより好ましい。該範囲の下限値以上であることにより、粘着性、架橋性、凝集性、耐水性が向上する。
特に、炭素数4〜12のアルキル基を含む(メタ)アクリル酸アルキルエステルから選ばれるモノマー単位と、カルボキシ基を含むモノマーから選ばれるモノマー単位とを有する重合体を用いる場合、該重合体を構成する全モノマー単位に対し、前者の割合は30〜99質量%が好ましく、50〜97質量%がより好ましい。後者の割合は1〜70質量%が好ましく、3〜50質量%がより好ましい。該範囲であることにより、上記の効果がより得られやすくなる。The proportion of the monomer units in the acrylic polymer (the total of the (meth) acrylic acid alkyl ester and the monomer containing the carboxyl group) is 10 to 100% by mass with respect to all monomer units constituting the acrylic polymer. Preferably, 40-100 mass% is more preferable. By being above the lower limit of the range, the tackiness, crosslinkability, cohesiveness, and water resistance are improved.
In particular, when a polymer having a monomer unit selected from a (meth) acrylic acid alkyl ester containing an alkyl group having 4 to 12 carbon atoms and a monomer unit selected from a monomer containing a carboxy group is used, the polymer is constituted. The proportion of the former is preferably from 30 to 99 mass%, more preferably from 50 to 97 mass%, based on all monomer units. The ratio of the latter is preferably 1 to 70% by mass, and more preferably 3 to 50% by mass. By being in this range, the above effects can be obtained more easily.
アクリル系高分子は、前記モノマー単位を提供するモノマー以外に、必要に応じて、前記モノマー単位を提供するモノマーと共重合可能なコモノマーを用いることができる。
係るコモノマーとしては、ビニルアルコール、2−ヒドロキシ(メタ)アクリレート、ヒドロキシプロピル(メタ)アクリレート、(メタ)アクリル酸ヒドロキシエチルエステルのような水酸基含有単量体;スチレンスルホン酸、アリルスルホン酸、スルホプロピルアクリレートのようなスルホン基含有単量体;ジメチルアミノエチルアクリレート、ビニルピロリドンのようなアミノ基含有単量体;(メタ)アクリルアミド、ジメチル(メタ)アクリルアミド、N−ブチル(メタ)アクリルアミドのようなアミド基含有アクリル系単量体;(メタ)アクリル酸アミノエチルエステル、(メタ)アクリル酸ジメチルアミノエチルエステル、(メタ)アクリル酸ジエチルアミノエチルエステルのようなアルキルアミノ基含有アクリル系単量体;(メタ)アクリル酸メトキシエチルエステル、(メタ)アクリル酸エトキシエチルエステルのようなアルコキシ基(又は側鎖にエーテル結合)含有単量体;(メタ)アクリル酸グリコシルオキシエチル、(メタ)アクリル酸ガラクトシルオキシエチルのような糖鎖含有単量体;N−(メタ)アクリロイルアミノ酸のようなビニル系単量体;アクリル酸のウレタンエステル、尿素エステル、イソシアネートエステルのようなアクリル系単量体;(メタ)アクリロニトリル、酢酸ビニル、プロピオン酸ビニル、ビニルクロライド、ビニルピリジン、ビニルピラジン、ビニルピペラジン、ビニルピペリドン、ビニルピリミジン、ビニルピロール、ビニルイミダゾール、ビニルカプロラクタム、ビニルオキサゾール、ビニルチアゾール、ビニルモルホリン、スチレン、α−メチルスチレン、ビス(N,N−ジメチルアミノエチル)マレエートなどのビニル系単量体等が挙げられる。
これらのコモノマーは、1種単独で用いてもよく、2種以上を併用してもよい。
上記コモノマーにより提供されるモノマー単位の割合は、該アクリル系高分子を構成する全モノマー単位に対し、50質量%以下であることが好ましい。As the acrylic polymer, in addition to the monomer that provides the monomer unit, a comonomer that can be copolymerized with the monomer that provides the monomer unit can be used as necessary.
Such comonomers include hydroxyl-containing monomers such as vinyl alcohol, 2-hydroxy (meth) acrylate, hydroxypropyl (meth) acrylate, and (meth) acrylic acid hydroxyethyl ester; styrene sulfonic acid, allyl sulfonic acid, sulfopropyl Sulfon group-containing monomers such as acrylates; Amino group-containing monomers such as dimethylaminoethyl acrylate and vinylpyrrolidone; Amides such as (meth) acrylamide, dimethyl (meth) acrylamide, and N-butyl (meth) acrylamide Group-containing acrylic monomer; alkylamino group-containing acrylic monomer such as (meth) acrylic acid aminoethyl ester, (meth) acrylic acid dimethylaminoethyl ester, (meth) acrylic acid diethylaminoethyl ester; A) Monomers containing alkoxy groups (or ether bonds in the side chain) such as methoxyethyl acrylate and ethoxyethyl methacrylate; glycosyloxyethyl (meth) acrylate, galactosyloxy (meth) acrylate Sugar chain-containing monomers such as ethyl; vinyl monomers such as N- (meth) acryloylamino acids; acrylic monomers such as urethane esters, urea esters and isocyanate esters of acrylic acid; Acrylonitrile, vinyl acetate, vinyl propionate, vinyl chloride, vinylpyridine, vinylpyrazine, vinylpiperazine, vinylpiperidone, vinylpyrimidine, vinylpyrrole, vinylimidazole, vinylcaprolactam, vinyloxazole, vinylthiazole, vinylmorpholine , Styrene, alpha-methyl styrene, bis (N, N-dimethylaminoethyl) vinyl monomers, such as maleate, and the like.
These comonomers may be used individually by 1 type, and may use 2 or more types together.
The proportion of monomer units provided by the comonomer is preferably 50% by mass or less based on the total monomer units constituting the acrylic polymer.
前記アクリル系高分子は、たとえば重合開始剤を用いて合成することができる。
重合開始剤としては、過硫酸アンモニウム、過硫酸ナトリウム等の過硫酸塩;過酸化水素水、過酸化ラウロイル、t−ブチルハイドロパーオキサイド等の水性ラジカル重合開始剤またはそれらの混合物等が挙げられる。
重合開始剤の使用量は、係る合成に用いられるモノマーの全質量100質量部に対して0.01〜5質量部とすることが好ましく、0.1〜2質量部とすることがより好ましい。
また、重合開始剤と還元剤とを組み合わせてレドックス系を形成することもできる。
該還元剤としては、亜硫酸塩、亜硫酸水素塩、ピロ亜硫酸塩、ホルムアルデヒドスルホン酸塩等のアルカリ金属塩;アンモニウム塩、L−アスコルビン酸、酒石酸等のカルボン酸類が挙げられる。
還元剤の使用量は、係る合成に用いられるモノマーの全質量100質量部に対して0.01〜5質量部とすることが好ましく、0.1〜2質量部とすることがより好ましい。The acrylic polymer can be synthesized using, for example, a polymerization initiator.
Examples of the polymerization initiator include persulfates such as ammonium persulfate and sodium persulfate; aqueous radical polymerization initiators such as aqueous hydrogen peroxide, lauroyl peroxide and t-butyl hydroperoxide, or a mixture thereof.
The amount of the polymerization initiator used is preferably 0.01 to 5 parts by mass and more preferably 0.1 to 2 parts by mass with respect to 100 parts by mass of the total mass of monomers used for the synthesis.
Also, a redox system can be formed by combining a polymerization initiator and a reducing agent.
Examples of the reducing agent include alkali metal salts such as sulfites, hydrogen sulfites, pyrosulfites, and formaldehyde sulfonates; and carboxylic acids such as ammonium salts, L-ascorbic acid, and tartaric acid.
The amount of the reducing agent used is preferably 0.01 to 5 parts by mass, and more preferably 0.1 to 2 parts by mass with respect to 100 parts by mass of the total mass of the monomers used for the synthesis.
前記アクリル系高分子は、具体的には乳化重合によって、好ましく製造することができる。
乳化重合の際、用いられる界面活性剤としては、アニオン性界面活性剤、カチオン性界面活性剤、ノニオン性界面活性剤、両性界面活性剤またはそれらの混合物を用いることができる。
アニオン性界面活性剤としては、ラウリル硫酸ナトリウム、ドデシルベンゼンスルホン酸ナトリウムなどのアルキルもしくはアルキルアリル硫酸塩、アルキルもしくはアルキルアリルスルホン酸塩;ジアルキルスルホコハク酸塩;ポリオキシエチレン(3)ラウリルエーテル硫酸ナトリウム(エチレンオキシドの平均付加モル数が3)、ポリオキシエチレン(4)ラウリルエーテル硫酸ナトリウム(エチレンオキシドの平均付加モル数が4)などのポリオキシエチレンアルキルエーテル硫酸塩等が挙げられる。塩としては、アルカリ金属塩またはアンモニウム塩などが挙げられる。
ノニオン系界面活性剤としては、ポリオキシエチレンラウリルエーテル、ポリオキシエチレンオレイルエーテルなどのポリオキシエチレンアルキルエーテル;ポリオキシエチレンノニルフェニルエーテル、ポリオキシエチレンオクチルフェニルエーテルなどのポリオキシエチレンアルキルフェニルエーテル;モノラウリン酸ポリエチレングリコール、モノオレイン酸ポリエチレングリコールなどのポリオキシエチレン脂肪酸エステル等が挙げられる。
両性界面活性剤としては、ベタイン、アミノ酸の誘導体等が挙げられる。
また、ペプチド系界面活性剤であるサーファクチンナトリウムも挙げることができる。
これらの界面活性剤は、1種単独で用いてもよく、2種以上を併用してもよい。
界面活性剤の使用量は、係る合成に用いられるモノマーの全質量100質量部に対して0.1〜10質量部とすることが好ましく、0.5〜5質量部とすることがより好ましい。該使用量を0.1質量部以上とすることにより乳化重合反応がより安定に進行し、凝集物の生成が抑制される。一方、10質量部以下とすることにより乾燥性、耐水性が向上する。Specifically, the acrylic polymer can be preferably produced by emulsion polymerization.
As the surfactant used in the emulsion polymerization, an anionic surfactant, a cationic surfactant, a nonionic surfactant, an amphoteric surfactant or a mixture thereof can be used.
Examples of the anionic surfactant include alkyl or alkyl allyl sulfates such as sodium lauryl sulfate and sodium dodecylbenzene sulfonate, alkyl or alkyl allyl sulfonates; dialkyl sulfosuccinates; polyoxyethylene (3) sodium lauryl ether sulfates ( And polyoxyethylene alkyl ether sulfates such as polyoxyethylene (4) sodium lauryl ether sulfate (the average added mole number of ethylene oxide is 4) and the like. Examples of the salt include alkali metal salts and ammonium salts.
Nonionic surfactants include: polyoxyethylene alkyl ethers such as polyoxyethylene lauryl ether and polyoxyethylene oleyl ether; polyoxyethylene alkyl phenyl ethers such as polyoxyethylene nonylphenyl ether and polyoxyethylene octylphenyl ether; monolaurin And polyoxyethylene fatty acid esters such as polyethylene glycol acid and polyethylene glycol monooleate.
Examples of amphoteric surfactants include betaines and amino acid derivatives.
Moreover, Surfactin sodium which is a peptide-type surfactant can also be mentioned.
These surfactants may be used alone or in combination of two or more.
The amount of the surfactant used is preferably 0.1 to 10 parts by mass, more preferably 0.5 to 5 parts by mass with respect to 100 parts by mass of the total mass of monomers used for the synthesis. When the amount used is 0.1 parts by mass or more, the emulsion polymerization reaction proceeds more stably, and the formation of aggregates is suppressed. On the other hand, when the content is 10 parts by mass or less, the drying property and water resistance are improved.
また、前記乳化重合は、必要に応じて、エチレンジアミン四酢酸ナトリウムなどのキレート剤、ポリカルボン酸塩などの分散剤、リン酸塩、炭酸塩などの無機塩、チオール化合物、ハロゲン化合物などの連鎖移動剤の存在下で行うこともできる。該連鎖移動剤の存在下で行うことにより、得られるアクリル系高分子の分子量の制御が一定の範囲内で可能となる。 In addition, the emulsion polymerization may be performed by chain transfer of a chelating agent such as sodium ethylenediaminetetraacetate, a dispersing agent such as polycarboxylate, an inorganic salt such as phosphate and carbonate, a thiol compound, and a halogen compound, if necessary. It can also be carried out in the presence of an agent. By carrying out in the presence of the chain transfer agent, the molecular weight of the resulting acrylic polymer can be controlled within a certain range.
アクリル系高分子としてさらに具体的には、たとえば医薬品添加物事典2000(日本医薬品添加剤協会編集)に粘着剤として収載されている、アクリル酸・アクリル酸オクチルエステル共重合体、アクリル酸エステル・酢酸ビニルコポリマー、アクリル酸2−エチルヘキシル・ビニルピロリドン共重合体、アクリル酸2−エチルヘキシル・メタクリル酸2−エチルヘキシル・メタクリル酸ドデシル共重合体、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合樹脂エマルジョン、メタクリル酸・アクリル酸n−ブチルコポリマー、アクリル樹脂アルカノールアミン液に含有するアクリル系高分子等の粘着剤、DURO−TAKアクリル粘着剤シリーズ(商品名、ナショナルスターチアンドケミカル製)、オイドラギットシリーズ(商品名、樋口商会)等が好適に使用できる。 More specifically, examples of the acrylic polymer include acrylic acid / octyl acrylate copolymer, acrylic ester / acetic acid, which are listed as adhesives in, for example, Pharmaceutical Additives Dictionary 2000 (edited by Japan Pharmaceutical Additives Association). Vinyl copolymer, 2-ethylhexyl acrylate / vinyl pyrrolidone copolymer, 2-ethylhexyl acrylate / 2-ethylhexyl methacrylate / dodecyl methacrylate copolymer, methyl acrylate / 2-ethylhexyl acrylate copolymer resin emulsion, methacrylic acid・ N-butyl acrylate copolymer, adhesives such as acrylic polymers contained in acrylic resin alkanolamine liquid, DURO-TAK acrylic adhesive series (trade name, manufactured by National Starch and Chemical), Eudragit series (trade) Name, Higuchi Shokai), and the like can be suitably used.
本発明において、非水溶性高分子化合物(A)は、1種単独で用いてもよく、2種以上を併用してもよい。
非水溶性高分子化合物(A)の配合量は、非水系粘着剤組成物中、30〜95質量%であることが好ましく、より好ましくは50〜90質量%であり、特に好ましくは55〜85質量%である。該範囲の下限値以上であることにより、貼付剤を皮膚に適用した際の粘着性が向上し、貼付剤の皮膚からの剥がれ・めくれがより少なくなる。一方、上限値以下であることにより、貼付剤を皮膚から剥離した際の痛みが低減される。In this invention, a water-insoluble high molecular compound (A) may be used individually by 1 type, and may use 2 or more types together.
The blending amount of the water-insoluble polymer compound (A) is preferably 30 to 95% by mass, more preferably 50 to 90% by mass, and particularly preferably 55 to 85% in the non-aqueous pressure-sensitive adhesive composition. % By mass. By being more than the lower limit of the range, the adhesiveness when the patch is applied to the skin is improved, and the peeling and turning of the patch from the skin are further reduced. On the other hand, by being below the upper limit, pain when the patch is peeled from the skin is reduced.
<多価金属化合物(B)>
本発明においては、多価金属化合物(B)(以下、(B)成分ということがある。)が用いられる。該(B)成分を含有することによって、前記(A)成分と架橋反応し、貼付剤の皮膚に対しての粘着性を調整することができ、該粘着性の向上と、貼付剤を皮膚から剥離した際の痛みの抑制の効果が得られる。また、非水系粘着剤層用塗工液を調製した際、該非水系粘着剤層用塗工液の粘度変化が抑制されてライナーまたは支持体への塗工性が良好となり、貼付剤の製造性の向上の効果が得られる。<Polyvalent metal compound (B)>
In the present invention, a polyvalent metal compound (B) (hereinafter sometimes referred to as component (B)) is used. By containing the component (B), it is possible to adjust the adhesiveness of the patch to the skin by crosslinking reaction with the component (A). The effect of suppressing pain at the time of peeling is obtained. In addition, when a non-aqueous pressure-sensitive adhesive layer coating solution is prepared, the viscosity change of the non-aqueous pressure-sensitive adhesive layer coating solution is suppressed, and the coating property to the liner or the support becomes good, and the patch productivity is improved. The effect of improvement is obtained.
本発明において用いられる多価金属化合物(B)としては、マグネシウム化合物、カルシウム化合物、亜鉛化合物、アルミニウム化合物、チタン化合物、錫化合物、鉄化合物、マンガン化合物、コバルト化合物、ニッケル化合物等が挙げられる。なかでも、皮膚に対する安全性の点から、アルミニウム化合物、マグネシウム化合物、カルシウム化合物が好ましい。
これらのアルミニウム化合物、カルシウム化合物及びマグネシウム化合物は、いずれのものも好適に使用することができる。
具体的には、水酸化アルミニウム、硫酸アルミニウム、硫酸アルミニウムアンモニウム、硫酸アルミニウムカリウム、塩化アルミニウム、乳酸アルミニウム、ジヒドロキシアルミニウムアミノアセテート、酢酸アルミニウム、合成ケイ酸アルミニウム、メタケイ酸アルミニウム;硫酸カルシウム、硝酸カルシウム、塩化カルシウム、酢酸カルシウム、酸化カルシウム;水酸化マグネシウム、炭酸マグネシウム、硫酸マグネシウム、酢酸マグネシウム、酸化マグネシウム、水酸化アルミナ・マグネシウム、メタケイ酸アルミン酸マグネシウム、ケイ酸アルミン酸マグネシウム、合成ヒドロタルサイト、それらの金属原子を含む複塩等の水溶性化合物、水難溶性化合物が挙げられる。なかでも、貼付剤の皮膚に対しての粘着性や製造性の点から、水溶性多価金属化合物が好ましく、硫酸アルミニウム、硫酸アルミニウムアンモニウム、硫酸アルミニウムカリウム、塩化アルミニウム、乳酸アルミニウム、酢酸アルミニウム、硝酸カルシウム、塩化カルシウム、酢酸カルシウム、硫酸マグネシウム、酢酸マグネシウムが好ましく、硫酸アルミニウムカリウム、硫酸アルミニウムアンモニウム、乳酸アルミニウム、塩化アルミニウムが特に好ましい。
なお、本明細書および特許請求の範囲において「水溶性多価金属化合物」とは、20℃の水に対する溶解度が1mg/mL以上であり、好ましくは10mg/mL以上である多価金属化合物を示す。
これらの多価金属化合物(B)は、1種単独で用いてもよく、2種以上を併用してもよい。
多価金属化合物(B)の配合量は、アクリル系高分子の固形分100質量部に対し、0.01〜2質量部であることが好ましく、より好ましくは0.05〜1質量部であり、さらに好ましくは0.1〜1質量部である。該範囲の下限値以上であることにより、前記(A)成分との架橋性が高まって、貼付剤を皮膚から剥離する際の痛みがより抑制される。
一方、上限値以下であることにより、前記(A)成分との架橋が適度に制御され、貼付剤とした際の皮膚への粘着性がより向上する。Examples of the polyvalent metal compound (B) used in the present invention include magnesium compounds, calcium compounds, zinc compounds, aluminum compounds, titanium compounds, tin compounds, iron compounds, manganese compounds, cobalt compounds, nickel compounds and the like. Of these, aluminum compounds, magnesium compounds, and calcium compounds are preferred from the viewpoint of safety to the skin.
Any of these aluminum compounds, calcium compounds and magnesium compounds can be suitably used.
Specifically, aluminum hydroxide, aluminum sulfate, ammonium aluminum sulfate, aluminum potassium sulfate, aluminum chloride, aluminum lactate, dihydroxyaluminum aminoacetate, aluminum acetate, synthetic aluminum silicate, aluminum metasilicate; calcium sulfate, calcium nitrate, chloride Calcium, calcium acetate, calcium oxide; magnesium hydroxide, magnesium carbonate, magnesium sulfate, magnesium acetate, magnesium oxide, alumina hydroxide / magnesium, magnesium aluminate metasilicate, magnesium aluminate silicate, synthetic hydrotalcite, their metals Water-soluble compounds such as double salts containing atoms, and poorly water-soluble compounds are exemplified. Of these, water-soluble polyvalent metal compounds are preferred from the viewpoint of adhesiveness to the skin of the patch and manufacturability, and include aluminum sulfate, aluminum ammonium sulfate, potassium aluminum sulfate, aluminum chloride, aluminum lactate, aluminum acetate, nitric acid. Calcium, calcium chloride, calcium acetate, magnesium sulfate and magnesium acetate are preferred, and potassium aluminum sulfate, ammonium ammonium sulfate, aluminum lactate and aluminum chloride are particularly preferred.
In the present specification and claims, “water-soluble polyvalent metal compound” refers to a polyvalent metal compound having a solubility in water at 20 ° C. of 1 mg / mL or more, preferably 10 mg / mL or more. .
These polyvalent metal compounds (B) may be used alone or in combination of two or more.
The blending amount of the polyvalent metal compound (B) is preferably 0.01 to 2 parts by mass, more preferably 0.05 to 1 part by mass with respect to 100 parts by mass of the solid content of the acrylic polymer. More preferably, it is 0.1 to 1 part by mass. By being more than the lower limit of this range, the crosslinkability with the said (A) component increases, and the pain at the time of peeling a patch from skin is suppressed more.
On the other hand, by being below the upper limit, the crosslinking with the component (A) is appropriately controlled, and the adhesiveness to the skin when used as a patch is further improved.
<キレート剤(C)>
本発明の非水系粘着剤組成物においては、前記多価金属化合物(B)とキレートを形成するキレート剤(C)(以下、(C)成分ということがある。)をさらに含有することが好ましい。
該(C)成分は、前記多価金属化合物(B)が有する多価金属イオンとキレートを形成する能力を有する化合物である。該(C)成分を含有することによって、前記(A)成分と前記(B)成分との架橋性が制御される。これにより、貼付剤の製造において、非水系粘着剤組成物を含有する非水系粘着剤層用塗工液の粘度変化、特に粘度の増加が抑制されてライナーまたは支持体への塗工性が良好となり、貼付剤の製造性が向上すると共に、均一で良好な粘着剤層を有する貼付剤が得られる。
該キレート剤としては、エチレンジアミン、N−メチルエチレンジアミン、N,N’−ジメチルエチレンジアミン、N,N,N’,N’−テトラメチルエチレンジアミン、トリメチレンジアミン、cis−1,2−ジアミノシクロヘキサン、1,2,3−トリアミノプロパン、ジエチレントリアミン、トリエチレンテトラミン、ピリジン−2,6−ジカルボン酸、ニコチン酸ヒドラジド、ヒスタミン、イミノジ酢酸、ヒドロキシエチル酢酸、ニトリロトリ酢酸、N,N’−エチレンジアミンジ酢酸、N’−ヒドロキシエチル−N,N,N’−トリ酢酸、エチレンジアミン−N,N’−ジ酢酸−N,N’−ジプロピオン酸、エチレンジアミンテトラプロピオン酸、1,2−プロピレンジアミンテトラ酢酸、トリメチレンジアミンテトラ酢酸、trans−シクロヘキサン−1,2−ジアミンテトラ酢酸、エチルエーテルジアミンテトラ酢酸、ジエチレントリアミンペンタ酢酸、グリコールエーテルジアミンテトラ酢酸、グリシン、ザルコシン、アラニン、ロイシン、セリン、システイン、グルタミン酸、トリプトファン、アデニン、アセチルアセトン、2−ニトロソ−1−ナフトール−8−ヒドロキシナゾリン、クエン酸、リンゴ酸、酒石酸、エデト酸二ナトリウム、ジエチレントリアミン五酢酸、またはそれら化合物の一価金属塩(ナトリウム塩、カリウム塩等のアルカリ金属塩)、アミン塩、アンモニウム塩等が好ましく挙げられる。なかでも、クエン酸、エデト酸二ナトリウム、ジエチレントリアミン五酢酸、それら化合物の一価金属塩がより好ましい。
これらのキレート剤(C)は、1種単独で用いてもよく、2種以上を併用してもよい。
キレート剤(C)の配合量は、アクリル系粘着剤の固形分100質量部に対し、0.01〜5質量部であることが好ましく、より好ましくは0.1〜2質量部である。該範囲の下限値以上であることにより、非水系粘着剤組成物を含有する非水系粘着剤層用塗工液の粘度の増加が抑制されて、貼付剤の製造性が向上する。また、貼付剤とした際に皮膚への粘着性が向上する。一方、上限値以下であることにより、貼付剤を皮膚から剥離した際の痛みがより抑制される。<Chelating agent (C)>
The non-aqueous pressure-sensitive adhesive composition of the present invention preferably further contains a chelating agent (C) that forms a chelate with the polyvalent metal compound (B) (hereinafter also referred to as component (C)). .
The component (C) is a compound having the ability to form a chelate with the polyvalent metal ion of the polyvalent metal compound (B). By containing the component (C), the crosslinkability between the component (A) and the component (B) is controlled. As a result, in the manufacture of patches, the viscosity change of the non-aqueous pressure-sensitive adhesive layer coating solution containing the non-aqueous pressure-sensitive adhesive composition, particularly the increase in viscosity is suppressed, and the coating property to the liner or the support is good. Thus, the manufacturability of the patch is improved and a patch having a uniform and good pressure-sensitive adhesive layer is obtained.
Examples of the chelating agent include ethylenediamine, N-methylethylenediamine, N, N′-dimethylethylenediamine, N, N, N ′, N′-tetramethylethylenediamine, trimethylenediamine, cis-1,2-diaminocyclohexane, 1, 2,3-triaminopropane, diethylenetriamine, triethylenetetramine, pyridine-2,6-dicarboxylic acid, nicotinic acid hydrazide, histamine, iminodiacetic acid, hydroxyethylacetic acid, nitrilotriacetic acid, N, N′-ethylenediaminediacetic acid, N ′ -Hydroxyethyl-N, N, N'-triacetic acid, ethylenediamine-N, N'-diacetic acid-N, N'-dipropionic acid, ethylenediaminetetrapropionic acid, 1,2-propylenediaminetetraacetic acid, trimethylenediamine Tetraacetic acid, trans- Chlohexane-1,2-diaminetetraacetic acid, ethyl etherdiaminetetraacetic acid, diethylenetriaminepentaacetic acid, glycol etherdiaminetetraacetic acid, glycine, sarcosine, alanine, leucine, serine, cysteine, glutamic acid, tryptophan, adenine, acetylacetone, 2-nitroso -1-naphthol-8-hydroxynazoline, citric acid, malic acid, tartaric acid, disodium edetate, diethylenetriaminepentaacetic acid, or monovalent metal salts thereof (alkali metal salts such as sodium salts and potassium salts), amines Preferred examples include salts and ammonium salts. Of these, citric acid, disodium edetate, diethylenetriaminepentaacetic acid, and monovalent metal salts of these compounds are more preferable.
These chelating agents (C) may be used individually by 1 type, and may use 2 or more types together.
It is preferable that the compounding quantity of a chelating agent (C) is 0.01-5 mass parts with respect to 100 mass parts of solid content of an acrylic adhesive, More preferably, it is 0.1-2 mass parts. By being more than the lower limit of the range, an increase in the viscosity of the non-aqueous pressure-sensitive adhesive layer coating solution containing the non-aqueous pressure-sensitive adhesive composition is suppressed, and the productivity of the patch is improved. Moreover, when it is used as a patch, the adhesion to the skin is improved. On the other hand, by being below the upper limit, the pain when the patch is peeled from the skin is further suppressed.
本発明の非水系粘着剤組成物において、前記多価金属化合物(B)と前記キレート剤(C)との混合割合は、質量比で1/10〜5/1であることが好ましく、1/5〜3/1であることがより好ましい。該質量比において、(B)成分の割合が下限値以上であることにより、前記(A)成分との架橋性が高まって、貼付剤を皮膚から剥離する際の痛みがより抑制される。一方、(B)成分の割合が上限値以下であることにより、前記(A)成分との架橋が適度に制御され、貼付剤とした際の皮膚への粘着性がより向上する。 In the non-aqueous pressure-sensitive adhesive composition of the present invention, the mixing ratio of the polyvalent metal compound (B) and the chelating agent (C) is preferably 1/10 to 5/1 in terms of mass ratio. More preferably, it is 5 to 3/1. In the mass ratio, when the ratio of the component (B) is at least the lower limit, the crosslinkability with the component (A) is increased, and the pain when the patch is peeled from the skin is further suppressed. On the other hand, when the ratio of the component (B) is not more than the upper limit value, the crosslinking with the component (A) is appropriately controlled, and the adhesiveness to the skin when used as a patch is further improved.
<可塑剤(D)>
本発明の非水系粘着剤組成物においては、可塑剤(D)(以下、(D)成分ということがある。)をさらに含有することが好ましい。該(D)成分を含有することにより、貼付剤における非水系粘着剤層の皮膚に対する濡れ性が向上して密着性が高まると同時に、貼付剤を皮膚から剥がした際の痛みが低減される。
該(D)成分としては、二価アルコール(たとえば、エチレングリコール、プロピレングリコール、1,3−ブチレングリコール、ジエチレングリコール、ジプロピレングリコール、1,3−ヘキシレングリコールなど)、三価アルコール(たとえば、グリセリン、トリメチロールプロパンなど)、四価アルコール(たとえば、エリスリトール、ペンタエリスリトール、ジグリセリンなど)、五価アルコール(たとえば、キシリトールなど)、六価アルコール(たとえば、ソルビトール、ジペンタエリスリトールなど)等の多価アルコール;グルコース、マンノース、ショ糖、ソルビタン、トレハロース、アルキルグリコシド等の糖類;ポリエチレングリコール、ポリプロピレングリコール、ポリグリセリン等の多価アルコールの重合体;脂肪酸エステルまたはその誘導体、オクチルドデカノール等の炭素数8〜20の高級アルコールまたはその誘導体;オリーブ油、ヒマシ油等の油脂類などが挙げられる。なかでも、多価アルコール、脂肪酸エステル、油脂類が好ましく、特に上記の(D)成分を含有することによる効果が向上するとともに、薬物の経皮吸収性が良好なことから、脂肪酸エステルが好ましい。<Plasticizer (D)>
The non-aqueous pressure-sensitive adhesive composition of the present invention preferably further contains a plasticizer (D) (hereinafter sometimes referred to as component (D)). By containing the component (D), the wettability of the non-aqueous pressure-sensitive adhesive layer in the patch to the skin is improved and the adhesion is increased, and at the same time, pain when the patch is peeled from the skin is reduced.
Examples of the component (D) include dihydric alcohols (for example, ethylene glycol, propylene glycol, 1,3-butylene glycol, diethylene glycol, dipropylene glycol, 1,3-hexylene glycol), and trihydric alcohols (for example, glycerin). , Trimethylolpropane, etc.), tetrahydric alcohol (eg, erythritol, pentaerythritol, diglycerin, etc.), pentavalent alcohol (eg, xylitol, etc.), hexavalent alcohol (eg, sorbitol, dipentaerythritol, etc.), etc. Alcohol; sugars such as glucose, mannose, sucrose, sorbitan, trehalose, alkylglycoside; polymers of polyhydric alcohols such as polyethylene glycol, polypropylene glycol, polyglycerin; fats Ester, or derivatives thereof, higher alcohols or their derivatives having 8 to 20 carbon atoms such as octyldodecanol; olive oil, and the like fats and oils such as castor oil. Of these, polyhydric alcohols, fatty acid esters, and fats and oils are preferable, and fatty acid esters are particularly preferable because the effects of containing the component (D) are improved and the transdermal absorbability of the drug is good.
脂肪酸エステルとしては、なかでも下記一般式(1)で表される化合物が特に好ましい。
R2OOC−R1−R3 ・・・(1)
[式中、R1は炭素数3〜36の炭化水素基であり;R2は炭素数1〜20の炭化水素基であり;R3は水素原子または「−COOR4」で表される基である。R4は炭素数1〜10の炭化水素基である。]As the fatty acid ester, a compound represented by the following general formula (1) is particularly preferable.
R 2 OOC-R 1 -R 3 ··· (1)
[Wherein, R 1 is a hydrocarbon group having 3 to 36 carbon atoms; R 2 is a hydrocarbon group having 1 to 20 carbon atoms; R 3 is a hydrogen atom or a group represented by “—COOR 4 ”. It is. R 4 is a hydrocarbon group having 1 to 10 carbon atoms. ]
前記式(1)中、R1は、炭素数3〜36であり、好ましくは4〜20の炭化水素基を示し、直鎖状であっても分岐鎖状であってもよく、飽和であっても不飽和であってもよい。
また、R3が水素原子のときは、R1の炭素数は10〜36であることが好ましく、R3が「−COOR4」で表される基のときは、R1の炭素数は3〜20であることが好ましい。
R2は、炭素数1〜20、好ましくは1〜18の炭化水素基を示し、直鎖状であっても分岐鎖状であってもよく、飽和であっても不飽和であってもよい。また、R3が水素原子のときは、R2の炭素数は1〜18であることが好ましい。R3が「−COOR4」で表される基のときは、R2の炭素数は1〜10であることが好ましく、より好ましくは1〜6、さらに好ましくは1〜3である。
R4は炭素数1〜10の炭化水素基であり、好ましくは炭素数1〜8の炭化水素基を示し、該炭化水素基は直鎖状であっても分岐鎖状であってもよく、飽和であっても不飽和であってもよい。なお、R2とR4は、互いに同じであっても異なっていてもよい。
前記式(1)は、R3が水素原子のときはモノエステルであり、R3が「−COOR4」で表される基のときはジエステルである。In the formula (1), R 1 is a hydrocarbon group having 3 to 36 carbon atoms, preferably 4 to 20 carbon atoms, which may be linear or branched and saturated. Or unsaturated.
In addition, when R 3 is a hydrogen atom, the number of carbon atoms of R 1 is preferably 10 to 36, and when R 3 is a group represented by “—COOR 4 ”, the number of carbon atoms of R 1 is 3 It is preferably ~ 20.
R 2 represents a hydrocarbon group having 1 to 20 carbon atoms, preferably 1 to 18 carbon atoms, and may be linear or branched, and may be saturated or unsaturated. . Further, when R 3 is a hydrogen atom, the number of carbon atoms in R 2 is preferably 1 to 18. When R 3 is a group represented by “—COOR 4 ”, the carbon number of R 2 is preferably 1 to 10, more preferably 1 to 6, and further preferably 1 to 3.
R 4 is a hydrocarbon group having 1 to 10 carbon atoms, preferably a hydrocarbon group having 1 to 8 carbon atoms, and the hydrocarbon group may be linear or branched, It may be saturated or unsaturated. R 2 and R 4 may be the same as or different from each other.
Formula (1) is a monoester when R 3 is a hydrogen atom, and is a diester when R 3 is a group represented by “—COOR 4 ”.
脂肪酸エステルの具体例としては、ミリスチン酸イソプロピル、セバシン酸ジエチル、セバシン酸ジイソプロピル、アジピン酸ジイソプロピル、オレイン酸エチル、パルミチン酸イソプロピル、パルミチン酸オクチル、オレイン酸オレイル、ミリスチン酸イソトリデシル、ラウリン酸エチル等が挙げられる。なかでも、ミリスチン酸イソプロピル、セバシン酸ジエチル、セバシン酸ジイソプロピル、アジピン酸ジイソプロピル、パルミチン酸イソプロピル、パルミチン酸オクチル、オレイン酸オレイルが好ましい。 Specific examples of fatty acid esters include isopropyl myristate, diethyl sebacate, diisopropyl sebacate, diisopropyl adipate, ethyl oleate, isopropyl palmitate, octyl palmitate, oleyl oleate, isotridecyl myristate, ethyl laurate, etc. It is done. Of these, isopropyl myristate, diethyl sebacate, diisopropyl sebacate, diisopropyl adipate, isopropyl palmitate, octyl palmitate, and oleyl oleate are preferred.
これらの可塑剤(D)は、1種単独で用いてもよく、2種以上を併用してもよい。
可塑剤(D)の配合量は、アクリル系高分子の固形分100質量部に対し、5〜80質量部が好ましく、10〜80質量部がより好ましく、15〜75質量部がさらに好ましい。該範囲の下限値以上であることにより、貼付剤を皮膚から剥がした際の痛みがより低減される。また、薬物(E)の経皮吸収が高まり、製造性も向上する。一方、上限値以下であることにより、貼付剤とした際の皮膚への粘着性がより向上し、貼付剤が皮膚から剥がれにくくなる。These plasticizers (D) may be used individually by 1 type, and may use 2 or more types together.
5-80 mass parts is preferable with respect to 100 mass parts of solid content of an acrylic polymer, as for the compounding quantity of a plasticizer (D), 10-80 mass parts is more preferable, 15-75 mass parts is more preferable. By being more than the lower limit of the range, the pain when the patch is peeled from the skin is further reduced. In addition, the percutaneous absorption of the drug (E) is increased, and the productivity is improved. On the other hand, by being below the upper limit value, the adhesiveness to the skin when it is used as a patch is further improved, and the patch is difficult to peel off from the skin.
<薬物(E)>
本発明の非水系粘着剤組成物においては、薬物(E)(以下、(E)成分ということがある。)をさらに含有することが好ましい。該(E)成分を含有することにより、各薬物の薬効を有する貼付剤(医薬製剤)を提供することができる。
本発明において用いることができる薬物(E)は、その種類は特に限定されず、なかでも水難溶性薬物、一般に外用剤として経皮吸収し難いとされる薬物であっても使用可能である。
なお、「水難溶性薬物」とは、20℃の水に対する溶解度が0〜30mg/mLであり、好ましくは0〜10mg/mLである薬物を示す。
該(E)成分として具体的には、たとえばインドメタシン、フェルビナク、ケトプロフェン、フルルビプロフェン、ジクロフェナク、サリチル酸誘導体等の非ステロイド系抗炎症剤またはそのエステル誘導体;ジフェンヒドラミン等の抗ヒスタミン剤、塩酸イソプレナリン等の中枢神経作用薬;エストラジオール、テストステロン等のホルモン剤;アスピリン、アセトアミノフェン、イブプロフェン等の鎮痛剤;リン酸ジソピラミド等の抗不整脈用剤、塩酸トラゾリン等の冠血管拡張剤、リドカイン等の局所麻酔剤、塩化スキサメトニウム等の筋弛緩剤、クロトリマゾ−ル等の抗真菌剤、フルオロウラシル等の抗悪性腫瘍剤、塩酸タムスロシン等の排尿障害剤、ジアゼパム等の抗てんかん剤、メシル酸ブロモクリプチン等の抗パーキンソン病剤;フロセミド、クロニジン等の降圧剤;ニトログリセリン、硝酸イソソルビド等の血管拡張剤;ニコチン等の禁煙補助剤、ツロブテロール等の気管支拡張剤;フェノバルビタール、トリアゾラム等の催眠鎮静剤;フルフェナジン、テオリタジン等の精神安定剤;ビタミンA、ビタミンE、ビタミンK、オクトチアシン、リボフラビン酪酸エステル等のビタミン剤;プロスタグランジン類、スコポラミン、フェンタニール、トウガラシエキス、ノニル酸ワニリルアミドなどが挙げられる
上記薬効成分のなかでも、本発明の効果が特に顕著に得られることから、水難溶性薬物が好ましく、インドメタシン、フェルビナク、ケトプロフェン、フルルビプロフェン、ジクロフェナク、サリチル酸誘導体等の非ステロイド系抗炎症剤;エストラジオール、テストステロン等のホルモン剤;フロセミド、クロニジン等の降圧剤;ニトログリセリン、硝酸イソソルビド等の血管拡張剤、ニコチン等の禁煙補助剤、ツロブテロール等の気管支拡張剤、スコポラミン、フェンタニール、トウガラシエキス、ノニル酸ワニリルアミドがより好ましい。
これらの薬効成分は、1種を単独で用いてもよく、2種以上を組み合わせて用いてもよい。
薬効成分の配合量は、非水系粘着剤組成物中、それぞれの薬効成分における有効量とすることができる。
薬効成分の配合量としては、たとえば、非水系粘着剤組成物中、0.01〜65質量%程度であることが好ましい。<Drug (E)>
The non-aqueous pressure-sensitive adhesive composition of the present invention preferably further contains a drug (E) (hereinafter sometimes referred to as “component (E)”). By containing the component (E), a patch (pharmaceutical preparation) having a medicinal effect of each drug can be provided.
The kind of the drug (E) that can be used in the present invention is not particularly limited, and among them, it is possible to use even a poorly water-soluble drug, generally a drug that is hardly percutaneously absorbed as an external preparation.
The “poorly water-soluble drug” refers to a drug having a solubility in water at 20 ° C. of 0 to 30 mg / mL, preferably 0 to 10 mg / mL.
Specific examples of the component (E) include non-steroidal anti-inflammatory agents such as indomethacin, ferbinac, ketoprofen, flurbiprofen, diclofenac, and salicylic acid derivatives, or ester derivatives thereof; antihistamines such as diphenhydramine; Neuroactive agents; Hormonal agents such as estradiol and testosterone; analgesics such as aspirin, acetaminophen and ibuprofen; antiarrhythmic agents such as disopyramide phosphate; coronary vasodilators such as trazoline hydrochloride; local anesthetics such as lidocaine; Anti-Parkinson's disease such as muscle relaxants such as kissamethonium chloride, antifungal agents such as clotrimazole, antineoplastic agents such as fluorouracil, dysuria such as tamsulosin hydrochloride, antiepileptics such as diazepam, and bromocriptine mesylate Antihypertensive agents such as furosemide and clonidine; vasodilators such as nitroglycerin and isosorbide nitrate; smoking cessation aids such as nicotine; bronchodilators such as tulobuterol; hypnotic sedatives such as phenobarbital and triazolam; fluphenazine and theoritadine Tranquilizers; vitamins such as vitamin A, vitamin E, vitamin K, octothiacin, riboflavin butyrate; prostaglandins, scopolamine, fentanyl, red pepper extract, nonylic acid vanillylamide, etc. Since the effects of the invention can be obtained particularly remarkably, a poorly water-soluble drug is preferable, and non-steroidal anti-inflammatory agents such as indomethacin, felbinac, ketoprofen, flurbiprofen, diclofenac, salicylic acid derivatives; Hormonal agents such as testosterone; antihypertensive agents such as furosemide and clonidine; vasodilators such as nitroglycerin and isosorbide nitrate; smoking cessation aids such as nicotine; bronchodilators such as tulobuterol; Is more preferable.
One of these medicinal components may be used alone, or two or more thereof may be used in combination.
The compounding quantity of a medicinal ingredient can be made into the effective quantity in each medicinal ingredient in a non-aqueous adhesive composition.
As a compounding quantity of a medicinal component, it is preferable that it is about 0.01-65 mass% in a non-aqueous adhesive composition, for example.
<任意成分>
本発明の非水系粘着剤組成物においては、上記の成分以外に、本発明の効果を阻害しない範囲で、たとえば清涼化剤、温感剤、色素、香料、pH調整剤などの任意成分を含有させることができる。<Optional component>
In the non-aqueous pressure-sensitive adhesive composition of the present invention, in addition to the above-mentioned components, it contains optional components such as a cooling agent, a warming agent, a dye, a fragrance, and a pH adjuster, as long as the effects of the present invention are not impaired. Can be made.
本発明に用いることができるpH調整剤としては、たとえばアルカリ化合物等が挙げられる。具体的には、クエン酸ナトリウム、酢酸カリウム、酢酸ナトリウム、ジエタノールアミン、炭酸水素ナトリウム、炭酸ナトリウム、炭酸水素カリウム、炭酸カリウム、トリエタノールアミン、ジイソプロパノールアミン、トリイソプロパノールアミン、モノエタノールアミン、アンモニア水、水酸化カリウム、水酸化カルシウム、水酸化ナトリウム、水酸化マグネシウム、リン酸水素ナトリウム、リン酸三ナトリウム、リン酸二カリウム等が好ましく用いることができ、なかでもクエン酸ナトリウム、酢酸ナトリウム、ジエタノールアミン、炭酸水素ナトリウム、ジイソプロパノールアミン、トリエタノールアミン、トリイソプロパノールアミン、モノエタノールアミン、アンモニア水、水酸化カリウム、水酸化カルシウム、水酸化ナトリウム、リン酸水素ナトリウム、リン酸三ナトリウムがより好ましく、水酸化ナトリウム、水酸化カリウム、アンモニア水、炭酸水素ナトリウム、ジイソプロパノールアミンがさらに好ましい。
これらのpH調整剤は、1種を単独で用いてもよく、2種以上を組み合わせて用いてもよい。
pH調整剤の配合量は、たとえば後述する本発明の貼付剤の製造方法に記載のpHに調整するため、適量配合することができる。Examples of the pH adjuster that can be used in the present invention include alkali compounds. Specifically, sodium citrate, potassium acetate, sodium acetate, diethanolamine, sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, triethanolamine, diisopropanolamine, triisopropanolamine, monoethanolamine, aqueous ammonia, Potassium hydroxide, calcium hydroxide, sodium hydroxide, magnesium hydroxide, sodium hydrogen phosphate, trisodium phosphate, dipotassium phosphate, etc. can be preferably used, among which sodium citrate, sodium acetate, diethanolamine, carbonic acid Sodium hydrogen, diisopropanolamine, triethanolamine, triisopropanolamine, monoethanolamine, aqueous ammonia, potassium hydroxide, calcium hydroxide, sodium hydroxide , Sodium hydrogen phosphate, trisodium phosphate are more preferred, and sodium hydroxide, potassium hydroxide, aqueous ammonia, sodium bicarbonate, diisopropanolamine are more preferable.
These pH adjusters may be used alone or in combination of two or more.
The blending amount of the pH adjuster can be blended in an appropriate amount, for example, to adjust to the pH described in the method for producing the patch of the present invention described later.
本発明の非水系粘着剤組成物の調製方法は、特に限定されるものではないが、好ましくは、後述する本発明の貼付剤の製造方法に記載のライナーまたは支持体に塗工されてなる非水系粘着剤層の形成手段と同様の方法が用いられる。 The method for preparing the non-aqueous pressure-sensitive adhesive composition of the present invention is not particularly limited. Preferably, the non-aqueous pressure-sensitive adhesive composition is preferably applied to the liner or the support described in the method for producing the patch of the present invention described later. The same method as that for forming the aqueous pressure-sensitive adhesive layer is used.
≪貼付剤≫
本発明の貼付剤は、前記本発明の非水系粘着剤組成物が支持体に積層されてなるものである。≪Patch≫
The patch of the present invention is obtained by laminating the non-aqueous pressure-sensitive adhesive composition of the present invention on a support.
<支持体>
本発明の貼付剤に用いられる支持体としては、ポリエチレン、ポリウレタン・塩化ビニル共重合体、ポリウレタン、ポリエチレンエラストマー(たとえば、エチレンとα−オレフィンとの共重合体等)、ポリエステルエラストマー(たとえば、テレフタル酸ジメチルと1,4−ブチレングリコールとの共重合体等)等から選ばれる樹脂からなるフィルム、または前記フィルムと多孔性シートとが一体化されたものが好ましく用いられる。なかでも、ポリウレタンフィルム、ポリエチレンエラストマーフィルム、ポリエステルエラストマーフィルム、またはそれらフィルムと多孔性シートとが一体化されたものがより好ましく用いられる。
ここでいう多孔性シートとしては不織布、織布、編布等が好ましく用いられる。また、それらの繊維の材質としてはポリエステル、レーヨン、ナイロン、ポリプロピレン、ポリエチレン、ポリウレタン等が用いられる。
不織布を用いる場合、ニードルパンチ法、スパンレース法、スパンボンド法、ステッチボンド法、メルトブローン法等で製造した不織布が挙げられる。
前記樹脂からなるフィルムと多孔性シートとの一体化は、熱融着、接着剤等による接着や、多孔性シートに溶融した樹脂を押し出しながら一体成形する方法等により行うことができる。
樹脂からなるフィルムの厚さは、特に制限はないが、5〜500μmであることが好ましく、より好ましくは7〜300μmであり、さらに好ましくは10〜200μmである。該範囲であれば、適度な透湿性と伸縮性の両方が得られ、貼付剤としたときに良好な使用感(貼りやすさなど)が得られる。
支持体の透湿度は、8000g/m2/24hr以下であることが好ましく、より好ましくは100〜4000g/m2/24hrであり、さらに好ましくは100〜3000g/m2/24hrである。該範囲の上限値以下であれば、薬物の経皮吸収性を低下させずに、良好な皮膚への粘着力と使用感が得られる。他方、特に100g/m2/24hr以上であれば、貼付剤使用時の皮膚刺激が緩和される。
支持体の透湿度は、前記フィルムの厚さや、親水度、多孔度、多孔性シートの目付けの程度などにより調整することができる。
なお、前記支持体の透湿度は、JIS一般試験法「防湿包装材料の透湿度試験法(カップ法)」(JIS Z 0208−1976)の条件Bにより測定される値を示す。<Support>
Examples of the support used in the patch of the present invention include polyethylene, polyurethane / vinyl chloride copolymer, polyurethane, polyethylene elastomer (for example, a copolymer of ethylene and α-olefin), and polyester elastomer (for example, terephthalic acid). A film made of a resin selected from a copolymer of dimethyl and 1,4-butylene glycol or the like, or a film in which the film and a porous sheet are integrated is preferably used. Among these, a polyurethane film, a polyethylene elastomer film, a polyester elastomer film, or a film in which these films and a porous sheet are integrated is more preferably used.
Nonwoven fabric, woven fabric, knitted fabric and the like are preferably used as the porous sheet here. Further, polyester, rayon, nylon, polypropylene, polyethylene, polyurethane or the like is used as the material for these fibers.
When using a nonwoven fabric, the nonwoven fabric manufactured by the needle punch method, the spunlace method, the spun bond method, the stitch bond method, the melt blown method etc. is mentioned.
The film made of the resin and the porous sheet can be integrated by heat fusion, bonding with an adhesive, or the like, or a method of integrally forming the molten resin while extruding the porous sheet.
Although there is no restriction | limiting in particular in the thickness of the film which consists of resin, It is preferable that it is 5-500 micrometers, More preferably, it is 7-300 micrometers, More preferably, it is 10-200 micrometers. If it is this range, both moderate moisture permeability and elasticity will be obtained, and when it is set as a patch, favorable usability (easiness of sticking etc.) will be obtained.
Moisture permeability of the support is preferably not more than 8000g / m 2 / 24hr, more preferably 100~4000g / m 2 / 24hr, more preferably from 100~3000g / m 2 / 24hr. If it is below the upper limit of the range, good skin adhesiveness and feeling of use can be obtained without reducing the transdermal absorbability of the drug. On the other hand, especially if 100g / m 2 / 24hr or more, skin irritation when the patch used is reduced.
The moisture permeability of the support can be adjusted by the thickness of the film, the hydrophilicity, the porosity, the basis weight of the porous sheet, and the like.
In addition, the moisture permeability of the said support body shows the value measured by the condition B of JIS general test method "moisture-proof packaging material moisture permeability test method (cup method)" (JIS Z 0208-1976).
さらに、支持体の非水系粘着剤組成物が積層されている(非水系粘着剤層)側の面は、必要に応じて、コロナ放電処理、プラズマ処理、表面の凸凹処理、オゾン照射、クロム酸処理、熱風処理、ポリウレタン樹脂によるアンカーコーティング等の表面処理が施されていてもよい。なかでも、貼付剤の投錨性(支持体と非水系粘着剤層との接着性)の向上効果及び操作性の点から、コロナ放電処理、プラズマ処理および表面の凸凹処理から選ばれる表面処理が施されていることが好ましい。 Furthermore, the surface of the support on which the non-aqueous pressure-sensitive adhesive composition is laminated (non-water-based pressure-sensitive adhesive layer) may be subjected to corona discharge treatment, plasma treatment, surface unevenness treatment, ozone irradiation, chromic acid as necessary. Surface treatment such as treatment, hot air treatment, anchor coating with polyurethane resin, etc. may be applied. Of these, surface treatment selected from corona discharge treatment, plasma treatment, and surface unevenness treatment is applied from the viewpoint of improving the operability of the patch (adhesion between the support and the non-aqueous adhesive layer) and operability. It is preferable that
本発明の貼付剤は、たとえば、前記本発明の非水系粘着剤組成物を含有する非水系粘着剤層用塗工液を調製し、該非水系粘着剤層用塗工液を、前記支持体上に塗工して積層させる方法により製造することができる。または、該非水系粘着剤層用塗工液を、ライナー上に塗工して積層し、その後、塗工層のライナー側の面とは反対側の面に、前記支持体を積層させる方法により製造することもできる。好ましくは、後述する本発明の貼付剤の製造方法と同様の方法により製造することができる。
ライナーとしては、塩化ビニルフィルム、ポリエチレンフィルム、ポリプロピレンフィルム、ポリエステルフィルム、薬添規ポリエチレンテレフタレートセパレータ、剥離紙(離型紙)等が好ましく用いられる。これらのライナーの非水系粘着剤層と接する面に対し、シリコン表面処理をすることにより、ライナーの非水系粘着剤層からの剥離性を向上させることができる。The patch of the present invention is prepared, for example, by preparing a nonaqueous adhesive layer coating solution containing the nonaqueous adhesive composition of the present invention, and applying the nonaqueous adhesive layer coating solution onto the support. It can manufacture by the method of apply | coating and laminating | stacking. Alternatively, the non-aqueous pressure-sensitive adhesive layer coating solution is coated on a liner and laminated, and then the support is laminated on the surface opposite to the liner-side surface of the coating layer. You can also Preferably, it can be produced by a method similar to the method for producing the patch of the present invention described later.
As the liner, a vinyl chloride film, a polyethylene film, a polypropylene film, a polyester film, a medicinal rule polyethylene terephthalate separator, a release paper (release paper), or the like is preferably used. The surface of these liners in contact with the non-aqueous pressure-sensitive adhesive layer can be treated with a silicon surface to improve the releasability of the liner from the non-aqueous pressure-sensitive adhesive layer.
また、本発明の貼付剤においては、支持体の非水系粘着剤層とは反対側の面に、貼付剤を使用する際に貼付操作がしやすいように、剥離可能な貼付用支持フィルムを積層し、貼付剤の層構成を(ライナー/非水系粘着剤層/支持体/貼付用支持フィルム)とすることが好ましい。これにより、貼付剤からライナーを剥がし、非水系粘着剤層側を皮膚に貼着し、貼付用支持フィルムを剥がす手順で、貼付剤を容易に貼付することができる。 In the patch of the present invention, a peelable support film for lamination is laminated on the surface of the support opposite to the non-aqueous pressure-sensitive adhesive layer so that the sticking operation is easy when using the patch. The layer structure of the patch is preferably (liner / non-aqueous pressure-sensitive adhesive layer / support / supporting film for sticking). Thereby, a patch can be easily stuck in the procedure which peels a liner from a patch, sticks the non-aqueous adhesive layer side to skin, and peels off the support film for sticking.
本発明の貼付剤は、ボールタック値(JIS Z 0237試験に準じ、傾斜角30°で測定したときの値)が好ましくは4〜25、より好ましくは4〜15となるように粘着力を調整することが好ましい。該範囲の下限値以上であれば、貼付剤の使用部位への密着性が充分に得られる。一方、上限値以下であれば、皮膚の痛みが少なく貼付剤を剥がすことができる。
貼付剤における粘着力は、非水溶性高分子化合物(A)、多価金属化合物(B)、可塑剤(D)の選択や配合量の制御などにより調整することができる。The adhesive patch of the present invention adjusts the adhesive strength so that the ball tack value (measured at an inclination angle of 30 ° according to JIS Z 0237 test) is preferably 4 to 25, more preferably 4 to 15. It is preferable to do. If it is more than the lower limit of this range, adhesiveness to the use site of the patch will be sufficiently obtained. On the other hand, if the amount is not more than the upper limit value, the patch can be peeled off with less skin pain.
The adhesive strength in the patch can be adjusted by selecting the water-insoluble polymer compound (A), the polyvalent metal compound (B), the plasticizer (D), controlling the blending amount, and the like.
また、本発明の貼付剤は、以下に示す方法により測定される透明度が、L*値として20以上であるものが好ましく、より好ましくは30以上であり、特に好ましくは40以上である。L*値は高いほど、透明性に優れて好ましいが、実質的には90以下である。
測定方法としては、色差計(日本電色工業(株)製、製品名:SE2000)を用いて、25℃にて透過法によって測定し、(L*、a*、b*)値を求め、その中のL*を指標とすることにより透明性を評価する。
なお、測定の標準として(X、Y、Z=94.59、92.57、111.43)なる特性値を有する標準白色板を用いる。In addition, the patch of the present invention preferably has a transparency measured by the method described below of 20 or more as an L * value, more preferably 30 or more, and particularly preferably 40 or more. The higher the L * value, the better the transparency, but it is practically 90 or less.
As a measurement method, using a color difference meter (manufactured by Nippon Denshoku Industries Co., Ltd., product name: SE2000), measurement is performed by a transmission method at 25 ° C., and (L *, a *, b *) values are obtained, Transparency is evaluated by using L * as an index.
A standard white plate having characteristic values (X, Y, Z = 94.59, 92.57, 111.43) is used as a measurement standard.
≪貼付剤の製造方法≫
本発明の貼付剤の製造方法は、多価金属化合物(B)と、該多価金属化合物(B)とキレートを形成するキレート剤(C)を含水溶媒に予め溶解し、pHを7以上に調整した混合溶液を調製した後、該混合溶液と、多価金属イオンと架橋点を形成する官能基を有する非水溶性高分子化合物(A)とを混合して水分散液を調製し、該水分散液を、ライナーまたは支持体に塗工し、乾燥して非水系粘着剤層を設ける製造方法である。≪Method for producing patch≫
In the method for producing the patch of the present invention, the polyvalent metal compound (B) and the chelating agent (C) that forms a chelate with the polyvalent metal compound (B) are previously dissolved in a water-containing solvent, and the pH is adjusted to 7 or more. After preparing the adjusted mixed solution, the aqueous solution is prepared by mixing the mixed solution and the water-insoluble polymer compound (A) having a functional group that forms a crosslinking point with the polyvalent metal ion, In this production method, an aqueous dispersion is applied to a liner or a support and dried to provide a non-aqueous pressure-sensitive adhesive layer.
本発明の貼付剤の製造方法は、たとえば、以下のようにして行うことができる。
多価金属化合物(B)とキレート剤(C)を含水溶媒に予め溶解し、pH調整剤等を用いてpHを7以上に、好ましくは8以上に、より好ましくは8〜12に、さらに好ましくは9〜12に調整した混合溶液(S)を調製する(pH:20℃における値)。pHを7以上とすることにより、非水溶性高分子化合物(A)と多価金属化合物(B)との架橋速度が制御され、水分散液(非水系粘着剤層用塗工液)の粘度変化が少なく、塗工ムラが生じ難く、均一な塗工が行いやすくなる。また、水分散液(非水系粘着剤層用塗工液)の調製後、該水分散液(非水系粘着剤層用塗工液)の経時に伴う粘着力の低下が抑制される。一方、pHを12以下とすることにより、該水分散液(非水系粘着剤層用塗工液)の粘度増加が抑制される。
含水溶媒とは、水を、溶媒全体に対し、40質量%以上、好ましくは60質量%以上、100質量%であってもよい溶媒を意味し、特に好ましくは水のみからなる溶媒である。
水以外の溶媒としては、エタノール、アセトン等を含有していてもよい。
混合溶液(S)中の(B)成分の含有量は、混合溶液(S)中、1〜15質量%とすることが好ましく、2〜8質量%とすることがより好ましい。
混合溶液(S)中の(C)成分の含有量は、混合溶液(S)中、1〜15質量%とすることが好ましく、2〜10質量%とすることがより好ましい。
なお、(B)成分、(C)成分、pH調整剤は、前記≪非水系粘着剤組成物≫において例示したものと同様のものを用いることができる。The method for producing the patch of the present invention can be performed, for example, as follows.
The polyvalent metal compound (B) and the chelating agent (C) are preliminarily dissolved in a water-containing solvent, and the pH is adjusted to 7 or higher, preferably 8 or higher, more preferably 8 to 12, more preferably using a pH adjuster or the like. Prepare a mixed solution (S) adjusted to 9-12 (pH: value at 20 ° C.). By setting the pH to 7 or more, the crosslinking rate between the water-insoluble polymer compound (A) and the polyvalent metal compound (B) is controlled, and the viscosity of the aqueous dispersion (non-aqueous pressure-sensitive adhesive layer coating solution) is controlled. There is little change, coating unevenness hardly occurs, and uniform coating is easy to perform. In addition, after the preparation of the aqueous dispersion (non-aqueous pressure-sensitive adhesive layer coating solution), a decrease in the adhesive strength with time of the aqueous dispersion (non-aqueous pressure-sensitive adhesive layer coating solution) is suppressed. On the other hand, by setting the pH to 12 or less, an increase in viscosity of the aqueous dispersion (non-aqueous pressure-sensitive adhesive layer coating liquid) is suppressed.
The water-containing solvent means a solvent which may be 40% by mass or more, preferably 60% by mass or more, and 100% by mass with respect to the whole solvent, and particularly preferably a solvent composed only of water.
As a solvent other than water, ethanol, acetone or the like may be contained.
The content of the component (B) in the mixed solution (S) is preferably 1 to 15% by mass and more preferably 2 to 8% by mass in the mixed solution (S).
The content of the component (C) in the mixed solution (S) is preferably 1 to 15% by mass and more preferably 2 to 10% by mass in the mixed solution (S).
In addition, as (B) component, (C) component, and a pH adjuster, the thing similar to what was illustrated in said << non-aqueous adhesive composition >> can be used.
混合溶液(S)とは別に、非水溶性高分子化合物(A)と、必要に応じて、可塑剤(D)、薬物(E)、任意成分のそれぞれの所定量を混合する。
次いで、これらの混合物を、溶剤と混合して、固形分が好ましくは30〜80質量%、より好ましくは40〜60質量%の混合溶液(T)を調製する。固形分を該範囲とすることにより、適度な粘度を有する混合溶液(T)が得られて取り扱いやすくなり、操作性が向上する。
溶剤としては、水;メタノール、エタノール、アセトン等の有機溶剤が挙げられ、なかでも水、エタノールが好ましく、水が最も好ましい。
また、非水溶性高分子化合物(A)は、操作性の点から、溶液またはエマルジョンとしたものを使用することが好ましい。その場合、溶液またはエマルジョン中の該(A)成分の含有量は30〜80質量%とすることが好ましく、40〜60質量%とすることがより好ましい。溶液またはエマルジョンに用いる溶剤としては、水、メタノール、エタノール、アセトン等が好ましく用いられる。
なお、(A)成分、(D)成分、(E)成分、任意成分は、前記≪非水系粘着剤組成物≫において説明したものと同様のものを用いることができる。Separately from the mixed solution (S), the water-insoluble polymer compound (A) and, if necessary, predetermined amounts of the plasticizer (D), the drug (E), and the optional component are mixed.
Subsequently, these mixtures are mixed with a solvent to prepare a mixed solution (T) having a solid content of preferably 30 to 80% by mass, more preferably 40 to 60% by mass. By setting the solid content in this range, a mixed solution (T) having an appropriate viscosity can be obtained and handled easily, and the operability is improved.
Examples of the solvent include water; organic solvents such as methanol, ethanol, and acetone. Among them, water and ethanol are preferable, and water is most preferable.
In addition, the water-insoluble polymer compound (A) is preferably used in the form of a solution or an emulsion from the viewpoint of operability. In that case, the content of the component (A) in the solution or emulsion is preferably 30 to 80% by mass, and more preferably 40 to 60% by mass. As the solvent used for the solution or emulsion, water, methanol, ethanol, acetone or the like is preferably used.
In addition, as (A) component, (D) component, (E) component, and arbitrary components, the thing similar to what was demonstrated in the said << non-aqueous adhesive composition >> can be used.
次に、混合溶液(S)と混合溶液(T)とを混合し、水分散液(非水系粘着剤層用塗工液)を調製する。
混合溶液(S)と混合溶液(T)との混合割合は、非水系粘着剤層を構成する非水系粘着剤組成物中において各成分が所望の配合量となるように調整する。
水分散液(非水系粘着剤層用塗工液)の全体が均一になるまで充分に撹拌した後、該水分散液(非水系粘着剤層用塗工液)を、ライナーまたは支持体に塗工する。
該水分散液(非水系粘着剤層用塗工液)の20℃での粘度は約300〜30000mPa・sとすることが好ましく、約1000〜10000mPa・sとすることがより好ましい。
なお、ここでいう粘度は、JIS Z8803に準じ、単一円筒形回転粘度計による粘度測定方法により測定される値を示す。
本発明においては、該水分散液(非水系粘着剤層用塗工液)の粘度変化が少なく、特に粘度増加が起こりにくく、ライナーまたは支持体に均一な厚さの塗工膜を容易に塗工することができる。
塗工方法としては、特に限定されず、通常選択されている方式、たとえば正回転ロールコーター、リバースロールコーター、グラビアコーター、ドクターナイフコーター、ブレードコーター、ロッドコーター、エアドクターコーター、カーテンコーター、ファウンテンコーター、キスコーター、浸漬塗工、スクリーン塗工、スピンコーター、キャスト塗工、スプレー塗工、押出コーター、真空塗工等を使用することができる。
該塗工液の塗工量は、乾燥後の固形分として1〜500g/m2とすることが好ましく、より好ましくは5〜250g/m2であり、さらに好ましくは10〜200g/m2である。該範囲の下限値以上とすることにより、貼付剤の粘着性が向上する。また、薬物の経皮吸収が高まる。一方、上限値以下とすることにより、一度の塗工処理によって非水系粘着剤層の形成が可能となる。
ライナーおよび支持体は、前記≪貼付剤≫において例示したものと同様のものを用いることができる。Next, the mixed solution (S) and the mixed solution (T) are mixed to prepare an aqueous dispersion (non-aqueous pressure-sensitive adhesive layer coating solution).
The mixing ratio of the mixed solution (S) and the mixed solution (T) is adjusted so that each component has a desired blending amount in the non-aqueous pressure-sensitive adhesive composition constituting the non-aqueous pressure-sensitive adhesive layer.
After stirring sufficiently until the entire aqueous dispersion (non-aqueous pressure-sensitive adhesive layer coating liquid) is uniform, the aqueous dispersion (non-aqueous pressure-sensitive adhesive layer coating liquid) is applied to the liner or support. Work.
The viscosity at 20 ° C. of the aqueous dispersion (non-aqueous pressure-sensitive adhesive layer coating solution) is preferably about 300 to 30000 mPa · s, more preferably about 1000 to 10000 mPa · s.
In addition, a viscosity here shows the value measured by the viscosity measuring method by a single cylindrical rotational viscometer according to JISZ8803.
In the present invention, there is little change in the viscosity of the aqueous dispersion (non-aqueous pressure-sensitive adhesive layer coating solution), and it is particularly difficult for the viscosity to increase, and a coating film having a uniform thickness is easily applied to the liner or the support. Can be crafted.
The coating method is not particularly limited and is usually selected, for example, a forward rotation roll coater, a reverse roll coater, a gravure coater, a doctor knife coater, a blade coater, a rod coater, an air doctor coater, a curtain coater, and a fountain coater. A kiss coater, dip coating, screen coating, spin coating, cast coating, spray coating, extrusion coating, vacuum coating or the like can be used.
The coating amount of the coating liquid is preferably 1 to 500 g / m 2 as the solid content after drying, more preferably 5 to 250 g / m 2 , and still more preferably 10 to 200 g / m 2 . is there. By setting it to be equal to or higher than the lower limit of the range, the adhesiveness of the patch is improved. In addition, percutaneous absorption of the drug is enhanced. On the other hand, by setting it to the upper limit value or less, it is possible to form a non-aqueous pressure-sensitive adhesive layer by a single coating process.
As the liner and the support, those similar to those exemplified in the above << Patch >> can be used.
その後、ライナーまたは支持体面に、水分散液(非水系粘着剤層用塗工液)を塗工後、溶剤を留去するために乾燥を行う。乾燥により、ライナーまたは支持体面に非水系粘着剤層を設けることができる。
該乾燥の方法は、たとえば熱風高速エアキャップ、熱風トンネル式、熱風エアフローティング、エアスルー、N2ガス置換乾燥システム、赤外線、マイクロ波、(電磁)誘導加熱、紫外線硬化、ランプ、反射板等の方法が挙げられる。なかでも、熱風高速エアキャップ、熱風トンネル式、熱風エアフローティングの方法を用いることが好ましい。
乾燥条件としては、非水溶性高分子化合物(A)が架橋される温度または溶媒類が揮散する温度以上とすることが好ましい。乾燥温度は40〜150℃とすることが好ましく、60〜130℃とすることがより好ましく、70〜120℃とすることがさらに好ましい。乾燥温度を40℃以上とすることにより溶媒類が容易に揮散することができる。一方、乾燥温度を150℃以下とすることにより、可塑剤(D)、薬物(E)等の熱に対する安定性が向上する。
また、乾燥時間(架橋時間)は15秒〜15分間とすることが好ましく、30秒〜10分間とすることがより好ましい。本発明においては、多価金属化合物(B)と非水溶性高分子化合物(A)を架橋させていることから、従来の架橋剤(たとえばイソシアネート系架橋剤等)を用いた場合よりも乾燥時間(架橋時間)を短くすることができる。Then, after applying an aqueous dispersion (non-aqueous pressure-sensitive adhesive layer coating solution) to the liner or support surface, drying is performed to distill off the solvent. By drying, a non-aqueous pressure-sensitive adhesive layer can be provided on the liner or the support surface.
Examples of the drying method include hot air high-speed air cap, hot air tunnel type, hot air air floating, air through, N2 gas replacement drying system, infrared, microwave, (electromagnetic) induction heating, ultraviolet curing, lamp, and reflector. Can be mentioned. Among them, it is preferable to use a hot air high-speed air cap, a hot air tunnel type, or a hot air air floating method.
The drying conditions are preferably set to a temperature at which the water-insoluble polymer compound (A) is crosslinked or a temperature at which the solvents are volatilized. The drying temperature is preferably 40 to 150 ° C, more preferably 60 to 130 ° C, and further preferably 70 to 120 ° C. By setting the drying temperature to 40 ° C. or higher, the solvents can be easily volatilized. On the other hand, by setting the drying temperature to 150 ° C. or lower, the stability to heat of the plasticizer (D), the drug (E) and the like is improved.
The drying time (crosslinking time) is preferably 15 seconds to 15 minutes, and more preferably 30 seconds to 10 minutes. In the present invention, since the polyvalent metal compound (B) and the water-insoluble polymer compound (A) are crosslinked, the drying time is longer than when a conventional crosslinking agent (for example, an isocyanate-based crosslinking agent) is used. (Crosslinking time) can be shortened.
支持体面に非水系粘着剤層を設けた場合、乾燥後、さらに、該非水系粘着剤層の支持体とは反対側の表面に、ライナーを積層し、全体を適当な大きさに裁断することにより、所望の大きさの貼付剤を得ることができる。
また、ライナー面に非水系粘着剤層を設けた場合、乾燥後、さらに、該非水系粘着剤層のライナー面とは反対側の表面に、支持体を積層し、全体を適当な大きさに裁断することにより、所望の大きさの貼付剤を得ることができる。When a non-aqueous pressure-sensitive adhesive layer is provided on the support surface, after drying, a liner is further laminated on the surface opposite to the support of the non-aqueous pressure-sensitive adhesive layer, and the whole is cut into an appropriate size. A patch of a desired size can be obtained.
When a non-aqueous pressure-sensitive adhesive layer is provided on the liner surface, after drying, a support is further laminated on the surface opposite to the liner surface of the non-aqueous pressure-sensitive adhesive layer, and the whole is cut into an appropriate size. By doing so, a patch of a desired size can be obtained.
本発明によれば、製造性に優れ、皮膚に対して良好な粘着性を有し、かつ剥離時の痛みが抑制された貼付剤を提供する非水系粘着剤組成物、貼付剤および貼付剤の製造方法を提供することができる。
本発明によれば、ライナーまたは支持体への塗工時に粘度変化が少なくて乾燥時間が短く、塗工適性に優れた非水系粘着剤層用塗工液を調製できる非水系粘着剤組成物を得ることができる。
本発明によれば、剥がれめくれがなく、剥がすときに痛くない貼付剤が得られる。
また、本発明の貼付剤は、皮膚に適用する粘着テープまたはシートとして使用することができる。
また、本発明の貼付剤は、消炎鎮痛や鎮痒などの即効性・持続性が期待される医薬製剤として特に好ましく使用することができる。According to the present invention, a non-aqueous pressure-sensitive adhesive composition, a patch, and a patch that provide a patch having excellent manufacturability, good adhesiveness to the skin, and reduced pain at the time of peeling. A manufacturing method can be provided.
According to the present invention, there is provided a non-aqueous pressure-sensitive adhesive composition capable of preparing a coating solution for a non-aqueous pressure-sensitive adhesive layer having a small change in viscosity when applied to a liner or a support, a short drying time, and excellent coating suitability. Obtainable.
According to the present invention, it is possible to obtain a patch that does not peel off and does not hurt when peeled off.
The patch of the present invention can be used as an adhesive tape or sheet applied to the skin.
In addition, the patch of the present invention can be particularly preferably used as a pharmaceutical preparation that is expected to have immediate effects and sustainability such as anti-inflammatory analgesia and antipruritics.
以下に実施例を用いて本発明をさらに詳しく説明するが、本発明はこれら実施例に限定されるものではない。また、例中の「部」および「%」は、特に断らない限り、水を除いた固形分であり、それぞれ質量部および質量%を示す。 Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited to these examples. Further, “parts” and “%” in the examples are solid contents excluding water unless otherwise specified, and indicate mass parts and mass%, respectively.
<貼付剤の製造>
下記の製造方法により、支持体上に各組成からなる非水系粘着剤層を有する貼付剤をそれぞれ製造した。非水系粘着剤層を構成する非水系粘着剤組成物の組成、支持体等について、実施例1は下記に、その他の例は表1にそれぞれ示した。<Manufacture of patches>
A patch having a non-aqueous pressure-sensitive adhesive layer having each composition on the support was produced by the following production method. Regarding the composition of the non-aqueous pressure-sensitive adhesive composition constituting the non-aqueous pressure-sensitive adhesive layer, the support and the like, Example 1 is shown below, and other examples are shown in Table 1, respectively.
(貼付剤の製造方法)
1)水20質量部(多価金属化合物1質量部に対し)に、多価金属化合物とキレート剤(または多価金属化合物のみ)を混合溶解し、必要に応じてpH調整剤によりpHを10に調整して混合溶液(S)を調製した。
2)別に、非水溶性高分子化合物と、薬物を溶解させた可塑剤との混合物とを混合して混合溶液(T)を調製した。(固形分:高分子により異なるが、50〜65%程度。)
3)混合溶液(S)に、混合溶液(T)を混合し、全体が均一になるまで充分に撹拌し、水分散液(非水系粘着剤層用塗工液、不揮発分50質量%)を調製した。その後、該水分散液(非水系粘着剤層用塗工液)を、乾燥後の膏体(非水系粘着剤組成物)の量が所定量となるように、ポリウレタンフィルム(支持体、シート状)に、コンマコーターにより塗工し、乾燥させた。乾燥は、熱風エアフローティングにより、90℃で5分間行った。
4)乾燥後、PETフィルムのシリコンコートを非水系粘着剤層面に覆い、全体を適当な大きさに裁断し、各例の貼付剤をそれぞれ得た。
なお、非水溶性高分子化合物(アクリル系粘着剤)の配合量は、pH調整剤を適量配合した場合は、該適量分を差し引いた値を示す。(Manufacturing method of patch)
1) A polyvalent metal compound and a chelating agent (or only a polyvalent metal compound) are mixed and dissolved in 20 parts by mass of water (with respect to 1 part by mass of the polyvalent metal compound), and the pH is adjusted to 10 with a pH adjuster as necessary. To prepare a mixed solution (S).
2) Separately, a mixed solution (T) was prepared by mixing a mixture of a water-insoluble polymer compound and a plasticizer in which a drug was dissolved. (Solid content: Depending on the polymer, it is about 50 to 65%.)
3) The mixed solution (S) is mixed with the mixed solution (S), and the mixture is sufficiently stirred until the whole becomes uniform, and an aqueous dispersion (non-aqueous pressure-sensitive adhesive layer coating solution, nonvolatile content 50% by mass) is obtained. Prepared. Thereafter, the aqueous dispersion (non-aqueous pressure-sensitive adhesive layer coating solution) is polyurethane film (support, sheet-like) so that the amount of the paste (non-aqueous pressure-sensitive adhesive composition) after drying becomes a predetermined amount. ) Were coated with a comma coater and dried. Drying was performed at 90 ° C. for 5 minutes by hot air air floating.
4) After drying, the silicone film of the PET film was covered with the surface of the non-aqueous pressure-sensitive adhesive layer, and the whole was cut into an appropriate size to obtain a patch of each example.
In addition, the compounding quantity of a water-insoluble high molecular compound (acrylic adhesive) shows the value which subtracted this suitable quantity, when a pH adjuster is mix | blended an appropriate quantity.
(実施例1)
非水系粘着剤組成物:アクリル系粘着剤4(非水溶性高分子化合物)80.00質量%、硫酸アルミニウムカリウム(多価金属化合物)0.50質量%、セバシン酸ジイソプロピル(可塑剤)15.00質量%、フェルビナク(薬物)0.50質量%、l−メントール(薬物)4.00質量%、水酸化カリウム(pH調整剤)適量。
非水系粘着剤層用塗工液の不揮発分(質量%):50質量%。
塗工方法:コンマコーター塗工。
支持体:下記ポリウレタンフィルムと同様。
ライナー:PETシリコンコート。
膏体の量(g/cm2):100(g/cm2)。(Example 1)
Non-aqueous pressure-sensitive adhesive composition: acrylic pressure-sensitive adhesive 4 (water-insoluble polymer compound) 80.00 mass%, potassium aluminum sulfate (polyvalent metal compound) 0.50 mass%, diisopropyl sebacate (plasticizer) 15. 00% by mass, felbinac (drug) 0.50% by mass, l-menthol (drug) 4.00% by mass, potassium hydroxide (pH adjuster) appropriate amount.
Nonvolatile content (mass%) of coating solution for non-aqueous pressure-sensitive adhesive layer: 50 mass%.
Coating method: Comma coater coating.
Support: Same as the following polyurethane film.
Liner: PET silicone coat.
Amount of plaster (g / cm 2 ): 100 (g / cm 2 ).
貼付剤の製造に用いた非水溶性高分子化合物、支持体の詳細について下記に示す。 Details of the water-insoluble polymer compound and the support used for the preparation of the patch are shown below.
[非水溶性高分子化合物]
アクリル系粘着剤1:アクリル酸2−エチルヘキシル/N−ビニル−2−ピロリドン/アクリル酸=75/22/3(質量比)。重合開始剤として過硫酸アンモニウム(前記モノマーの全質量100質量部に対して0.3質量部)を使用した。
アクリル系粘着剤2:アクリル酸2−エチルヘキシル/メタクリル酸メチル/アクリル酸=90/7/3(質量比)。重合開始剤として過硫酸アンモニウム(前記モノマーの全質量100質量部に対して0.3質量部)を使用した。
アクリル系粘着剤3: アクリル酸/アクリル酸オクチル=7/93(質量比)。重合開始剤として過硫酸アンモニウム(前記モノマーの全質量100質量部に対して0.3質量部)を使用した。
アクリル系粘着剤4:メタクリル酸・アクリル酸n−ブチルコポリマー(東レ・ダウコーニング製、商品名:MG−0581)。[Water-insoluble polymer compound]
Acrylic pressure-sensitive adhesive 1: 2-ethylhexyl acrylate / N-vinyl-2-pyrrolidone / acrylic acid = 75/22/3 (mass ratio). As a polymerization initiator, ammonium persulfate (0.3 parts by mass with respect to 100 parts by mass of the total mass of the monomer) was used.
Acrylic pressure-sensitive adhesive 2: 2-ethylhexyl acrylate / methyl methacrylate / acrylic acid = 90/7/3 (mass ratio). As a polymerization initiator, ammonium persulfate (0.3 parts by mass with respect to 100 parts by mass of the total mass of the monomer) was used.
Acrylic adhesive 3: Acrylic acid / octyl acrylate = 7/93 (mass ratio). As a polymerization initiator, ammonium persulfate (0.3 parts by mass with respect to 100 parts by mass of the total mass of the monomer) was used.
Acrylic adhesive 4: methacrylic acid / n-butyl acrylate copolymer (manufactured by Dow Corning Toray, trade name: MG-0581).
[支持体]
ポリウレタンフィルム:エステル系のポリウレタンフィルム、日清紡製、商品名:「モビロン(登録商標)フィルム」、厚さ30μm、透湿度1000g/m2/24hr、非水系粘着剤層との接着面:ポリウレタン不織布(厚さ30μm)積層。[Support]
Polyurethane Film: polyurethane film ester, Nisshinbo, trade name: "Mobilon (R) film" thickness of 30 [mu] m, moisture permeability 1000g / m 2 / 24hr, the adhesive surface of the non-aqueous adhesive layer: polyurethane nonwoven fabric ( 30 μm thick) laminated.
<評価方法>
下記に説明する塗工性、粘着性、剥離時の痛みのなさの評価をそれぞれ行った。結果を表1に併記した。なお、塗工性は、貼付剤の製造性の評価指標である。<Evaluation method>
The coating property, adhesiveness, and painlessness at the time of peeling described below were evaluated. The results are also shown in Table 1. The coatability is an evaluation index for manufacturability of the patch.
(1)塗工性
前記貼付剤の製造方法において調製された非水系粘着剤層用塗工液を、支持体面に、塗工膜の厚さが200μmとなるように、コンマコーターにより連続的に塗工した。
その際、塗工開始直後に対する塗工開始1時間後の非水系粘着剤層用塗工液の粘度、塗工膜の厚さの変化を、目視により観察し、塗工性を以下の基準に基づいて評価した。
◎:塗工開始直後と比較し、粘度変化がない、または粘度変化があってもわずかであり、均一な厚さの塗工膜を塗工することが可能な状態であった。
○:塗工開始直後と比較し、粘度は上昇するものの、均一な厚さの塗工膜を塗工することが可能な状態であった。
△:塗工開始直後と比較し、粘度は上昇し、塗工開始1時間後では均一な厚さの塗工膜を塗工することが不可能な状態であった。
×:塗工開始直後において粘度が高すぎるか、凝集物等の発生により塗工することが不可能な状態であった。(1) Coating property The non-aqueous pressure-sensitive adhesive layer coating solution prepared in the method for producing a patch is continuously applied to the support surface by a comma coater so that the thickness of the coating film is 200 μm. Coated.
At that time, the viscosity of the non-aqueous pressure-sensitive adhesive layer coating liquid and the change in the thickness of the coating film were observed by visual observation one hour after the start of coating, and the coating properties were determined based on the following criteria. Based on the evaluation.
(Double-circle): Compared with immediately after the start of coating, there was no change in viscosity, or even if there was a change in viscosity, it was a state in which a coating film having a uniform thickness could be applied.
○: Although the viscosity increased compared to immediately after the start of coating, it was possible to apply a coating film having a uniform thickness.
Δ: Viscosity increased compared to immediately after the start of coating, and it was impossible to apply a coating film having a uniform thickness 1 hour after the start of coating.
X: Viscosity was too high immediately after the start of coating, or coating was impossible due to generation of aggregates and the like.
(2)粘着性
各例の貼付剤(シート状)を7cm×10cmの大きさに裁断し、5名のパネラーの肘に貼付した。
貼付3時間後、貼付剤の肘からの剥がれ状態を、下記基準に基づく官能評価(目視観察)により評価した。
4点:貼付剤の全面が皮膚に密着していた。
3点:貼付剤の約20%未満の面積が剥がれていた。
2点:貼付剤の約20%以上50%未満の面積が剥がれていた。
1点:貼付剤の約50%以上の面積が剥がれていた。(2) Adhesiveness Each patch (sheet form) of each example was cut into a size of 7 cm × 10 cm and pasted on elbows of 5 panelists.
Three hours after application, the state of peeling of the patch from the elbow was evaluated by sensory evaluation (visual observation) based on the following criteria.
4 points: The entire surface of the patch was in close contact with the skin.
3 points: An area of less than about 20% of the patch was peeled off.
2 points: About 20% or more and less than 50% of the patch was peeled off.
1 point: About 50% or more of the patch was peeled off.
(3)剥離時の痛みのなさ
上記(2)粘着性の評価において、貼付3時間後に貼付剤を肘から剥離し、その時の皮膚刺激を下記基準に基づいて評価した。
4点:全く痛みがなかった。
3点:やや痛みはあったが、気にならない程度であった。
2点:かなり痛みを感じた。
1点:非常に痛みを感じた。
上記皮膚刺激の評価結果から、5名のパネラーの平均点を算出し、下記基準に基づいて剥離時の痛みのなさを評価した。
◎:3.5点以上。
○:2.5点以上3.5点未満。
△:1.5点以上2.5点未満。
×:1.5点未満。(3) No pain at the time of peeling In the above (2) evaluation of adhesiveness, the patch was peeled from the elbow 3 hours after sticking, and the skin irritation at that time was evaluated based on the following criteria.
4 points: There was no pain at all.
3 points: Although there was some pain, it was a level not to worry about.
2 points: I felt a lot of pain.
1 point: I felt very painful.
From the skin irritation evaluation results, the average score of 5 panelists was calculated, and the absence of pain was evaluated based on the following criteria.
A: 3.5 points or more.
○: 2.5 points or more and less than 3.5 points.
Δ: 1.5 points or more and less than 2.5 points.
X: Less than 1.5 points.
非水溶性高分子化合物と多価金属化合物を含有する、本発明に係る実施例1の貼付剤は、いずれの評価項目も良好であり、製造性に優れ、皮膚に対して良好な粘着性を有し、かつ剥離時の痛みが抑制されていることが確認できた。 The patch of Example 1 according to the present invention containing a water-insoluble polymer compound and a polyvalent metal compound is good in all evaluation items, excellent in manufacturability, and has good adhesiveness to the skin. It was confirmed that the pain at the time of peeling was suppressed.
表1の結果から、非水溶性高分子化合物と多価金属化合物と、さらにキレート剤を含有する、本発明に係る実施例2〜13の貼付剤は、いずれの評価項目も良好であることから、製造性に優れ、皮膚に対して良好な粘着性を有し、かつ剥離時の痛みが抑制されていることが確認できた。
一方、多価金属化合物(B)を含有しない、本発明とは異なる比較例1は、剥離時の痛みのなさが悪かった。From the results of Table 1, the patches of Examples 2 to 13 according to the present invention, which contain a water-insoluble polymer compound, a polyvalent metal compound, and a chelating agent, all have good evaluation items. It was confirmed that it was excellent in manufacturability, had good adhesiveness to the skin, and pain at the time of peeling was suppressed.
On the other hand, Comparative Example 1, which does not contain the polyvalent metal compound (B) and is different from the present invention, was poor in pain during peeling.
本発明によれば、製造性に優れ、皮膚に対して良好な粘着性を有し、かつ剥離時の痛みが抑制された貼付剤を提供する非水系粘着剤組成物、貼付剤および貼付剤の製造方法を提供することができる。 According to the present invention, a non-aqueous pressure-sensitive adhesive composition, a patch, and a patch that provide a patch having excellent manufacturability, good adhesiveness to the skin, and reduced pain at the time of peeling. A manufacturing method can be provided.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008513298A JP5130203B2 (en) | 2006-04-28 | 2007-04-27 | Non-aqueous adhesive composition, patch and method for producing the patch |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006126716 | 2006-04-28 | ||
JP2006126716 | 2006-04-28 | ||
JP2008513298A JP5130203B2 (en) | 2006-04-28 | 2007-04-27 | Non-aqueous adhesive composition, patch and method for producing the patch |
PCT/JP2007/059206 WO2007126067A1 (en) | 2006-04-28 | 2007-04-27 | Nonaqueous pressure-sensitive adhesive composition, patches and process for production of patches |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2007126067A1 true JPWO2007126067A1 (en) | 2009-09-10 |
JP5130203B2 JP5130203B2 (en) | 2013-01-30 |
Family
ID=38655588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008513298A Active JP5130203B2 (en) | 2006-04-28 | 2007-04-27 | Non-aqueous adhesive composition, patch and method for producing the patch |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP5130203B2 (en) |
KR (1) | KR101342756B1 (en) |
CN (1) | CN101432383B (en) |
WO (1) | WO2007126067A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102046171B (en) * | 2008-05-30 | 2013-06-19 | 日东电工株式会社 | Transdermal preparation |
JP5368168B2 (en) * | 2008-06-16 | 2013-12-18 | 日東電工株式会社 | Patches and patch preparations |
CN102065900B (en) * | 2008-06-23 | 2013-09-25 | 东亚荣养株式会社 | Percutaneous absorption enhancer and transdermal preparation using the same |
KR101658504B1 (en) * | 2009-07-30 | 2016-09-21 | 스미토모 세이카 가부시키가이샤 | Water-soluble polymer composition, composition for forming plaster layer of skin patch, and skin patch |
JP5615899B2 (en) * | 2010-02-24 | 2014-10-29 | 久光製薬株式会社 | Transdermal absorption preparation |
US9370495B2 (en) * | 2010-02-24 | 2016-06-21 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch |
US9376547B2 (en) | 2013-03-14 | 2016-06-28 | Kaneka Corporation | Polymer production method |
CN107001866B (en) * | 2014-12-26 | 2021-05-04 | 日绊株式会社 | Adhesive material |
JPWO2016129596A1 (en) | 2015-02-13 | 2017-11-24 | 株式会社カネカ | Method for producing particulate polymer |
JP6531452B2 (en) * | 2015-03-23 | 2019-06-19 | 東洋インキScホールディングス株式会社 | Pressure-sensitive adhesive composition and pressure-sensitive adhesive sheet |
KR102122583B1 (en) | 2016-02-23 | 2020-06-15 | 주식회사 엘지화학 | Adhesive tape and method of manufacturing thereof |
KR20190039939A (en) * | 2016-08-09 | 2019-04-16 | 닛토덴코 가부시키가이샤 | A skin patch and a skin patch member |
JP7369552B2 (en) * | 2018-06-29 | 2023-10-26 | ニチバン株式会社 | medical patch |
WO2020183636A1 (en) * | 2019-03-13 | 2020-09-17 | 互応化学工業株式会社 | Binder composition for producing green sheet, slurry composition for firing, method for producing green sheet, method for producing sintered body, and method for producing layered ceramic capacitor |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57176908A (en) * | 1981-04-23 | 1982-10-30 | Sekisui Chem Co Ltd | Remedial adhesive tape or sheet |
JPH02311549A (en) * | 1989-05-26 | 1990-12-27 | Taisho Pharmaceut Co Ltd | Production of gel |
JP2700835B2 (en) * | 1989-12-28 | 1998-01-21 | 日東電工株式会社 | Acrylic gel material and acrylic gel preparation |
DK0507878T3 (en) * | 1989-12-28 | 1995-07-31 | Minnesota Mining & Mfg | Composite of a dispersed gel in an adhesive matrix and process for its preparation |
JP4275768B2 (en) * | 1998-06-18 | 2009-06-10 | 久光製薬株式会社 | Aqueous adhesive paste |
JP2002272831A (en) * | 2001-03-14 | 2002-09-24 | Fumio Kamiyama | Wound coating tacky adhesive sheet |
JP5021124B2 (en) * | 2001-08-29 | 2012-09-05 | 日東電工株式会社 | Medical adhesive composition, medical adhesive tape and transdermal absorption tape formulation using the same |
JP4799879B2 (en) * | 2005-02-17 | 2011-10-26 | 日東電工株式会社 | Adhesive, and adhesive tape and transdermal absorption preparation using the same |
-
2007
- 2007-04-27 JP JP2008513298A patent/JP5130203B2/en active Active
- 2007-04-27 WO PCT/JP2007/059206 patent/WO2007126067A1/en active Application Filing
- 2007-04-27 CN CN2007800147979A patent/CN101432383B/en active Active
-
2008
- 2008-10-21 KR KR1020087025669A patent/KR101342756B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
JP5130203B2 (en) | 2013-01-30 |
KR20080111080A (en) | 2008-12-22 |
WO2007126067A1 (en) | 2007-11-08 |
CN101432383A (en) | 2009-05-13 |
KR101342756B1 (en) | 2013-12-19 |
CN101432383B (en) | 2013-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5130203B2 (en) | Non-aqueous adhesive composition, patch and method for producing the patch | |
US7691404B2 (en) | Transdermal delivery system of diclofenac with improved water absorbability and adhesion properties | |
JP5185509B2 (en) | Patch | |
US7029693B2 (en) | Percutaneously absorptive preparation | |
JP7257410B2 (en) | Hydrous patch | |
TW200524581A (en) | Tulobuterol adhesive patch | |
JP2003093434A (en) | Elastic poultice for external application | |
CA2719364C (en) | Butenafine hydrochloride-containing aqueous patch | |
JP4331984B2 (en) | Aqueous emulsion adhesive for medical percutaneous absorption tape preparation, medical percutaneous absorption tape preparation and production method thereof | |
JP2008162975A (en) | Non-aqueous warm sensation self-adhesive composition and warm sensation plaster | |
WO2010125691A1 (en) | Adhesive patch | |
TWI687230B (en) | Substrate for patch and patch using the same | |
JPH0429927A (en) | Plaster | |
WO2021192270A1 (en) | Hydrous patch | |
WO2021193874A1 (en) | Transdermal patch | |
WO2022064607A1 (en) | Hydrous patch for drug | |
JP2024048993A (en) | Patches | |
WO2022064608A1 (en) | Hydrous adhesive patch for non-medical product | |
JP2022131753A (en) | Non-aqueous patch | |
JP6418977B2 (en) | Transdermal absorption enhancer for patches and non-steroidal anti-inflammatory agents | |
JP2022142438A (en) | Water-containing patch with moisture sensor function | |
JPH1149669A (en) | Antiviral agent-containing tape preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100223 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120717 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120914 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121009 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121105 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5130203 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151109 Year of fee payment: 3 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |